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"Infectious disease is one of the few genuine adventures left in the world. The 
dragons are all dead and the lance grows rusty in the chimney comer....About the 
only sporting proposition that remains unimpaired by the relentless domestication 
of a once free-living human species is the war against those ferocious little fellow 
creatures, which lurk in the dark comers and stalk us in the bodies of rats, mice and 
all kinds of domestic animals; which fly and crawl with the insects, and waylay us 
in our food and drink and even in our love."
This quote is taken from the book RATS, LICE AND HISTORY written in 1935 by 
the great microbiologist Hans Zinsser, as he reflected on his life in science and 
medicine and on his efforts to develop the means for preventing typhus and other 
infectious diseases. Hans Zinsser’s thought has challenged several generations of 
microbiologists and infectious disease specialists, and now it challenges another 
generation, including the staff of the Center for Infectious Diseases at the Centers 
for Disease Control. The staff of the Center looks to the demanding challenges of 
today and tomorrow with the same sense of commitment that guided Hans 
Zinsser.
It is hoped that this brochure may entice some readers to take up the same 
challenge— to inquire further into one of the medical microbiologic/infectious 
diseases subjects or programs described—to inquire further into career 
opportunities in these sciences— to inquire further into career opportunities in 
public service. We would be delighted to respond to any such inquiries.
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THE CENTER FO R  IN FECTIO U S D ISEA SES: TOW ARD THE YEAR 2000
There is a revolution under way in 
medical bacteriology, virology, myco­
logy, parasitology, and related clinical 
sciences that promises great progress in 
the prevention and control of the impor­
tant infectious diseases still burdening 
the people of the United States and the 
rest of the world. The revolution is rep­
resented by an incredible pace of tech­
nological development and conceptual 
change— and by the promise of even 
greater development and change in the 
future. The staff of the Center for Infec­
tious Diseases at the Centers for Disease 
Control is participating in this revolu­
tion, making substantial contributions, 
often in a leadership role, often in a 
partnership role with colleagues in State 
and local health departments and other 
medical, biomedical, and public health 
institutions.
The history of the sciences at the heart 
of today's programs for the prevention 
and control of infectious diseases is 
brief, spanning only about a century, 
but it is crowded with wonderful dis­
coveries and practical applications. This 
history centers on the replacement of 
centuries-old beliefs, conceptions, and 
theories by scientific proofs. Scientific 
proofs established the concept of speci­
ficity of infectious disease causation— 
that is, infectious diseases are caused 
not by some common miasma (a myste­
riously poisonous substance), but rather 
by specific infectious agents. This con­
cept led to the introduction of specific 
prevention and control strategies, 
specific diagnostic tests, and specific 
therapeutic approaches. This reforma­
tion of medical thought involved bitter 
struggle against entrenched opposition, 
but in the end the scientific method, the 
experimental and investigative method, 
won out.
In a larger sense, the 
m icrobiologic/infec­
tious disease sciences 
have played a para­
mount role in the 
reformation of medical 
thought, overall. The 
concept of specificity of 
disease causation and 
the requirement for veri­
fiable scientific proofs 
have been extended uni­
versally throughout all 
medical sciences. At the 
same time, the practical 
application of the micro­
biologic/infectious dis­
ease sciences has led to 
improvements in human 
health and well-being 
that have exceeded the 
contribution of any 
other branch of science.
the microbiologic / 
infectious disease 
sciences have played 
a paramount role in 
the reformation of 
medical thought, 
overall
the concept of 
specificity of disease 
causation and the 
requirement for 
verifiable scientific 
proofs, which 
originated in 
microbiology, have 
been extended 
universally 
throughout all 
medical sciences
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Proof of this practical value of the 
microbiologic/infectious disease sci­
ences is seen in the effect of scientific 
breakthroughs on life expectancy 
worldwide— for example, the great 
risk of death of mother and baby at 
childbirth from bacterial sepsis, which 
was so common in the 19th century, 
has been eliminated by the application 
of aseptic gynecologic techniques. 
Similarly, aseptic techniques have 
allowed the marvelous achievements 
of modern surgery.
For centuries, the "great epidemic dis­
eases" were the most common causes 
of death everywhere in the world—  
today, many of these diseases are 
threats only when vigilance and sup­
port for public health programs fail.
THE GREAT EPIDEMIC DISEASES
CONTROLLABLE BY CONTROLLABLE BY CONTROLLABLE BY
HYGIENE VACCINE CHEMOTHERAPY
PLAGUE SMALLPOX* SCARLET FEVER
TYPHUS MEASLES MALARIA**
TYPHOID FEVER INFLUENZA
CHOLERA POLIO
DIPHTHERIA
YELLOW FEVER’1'*
* ERADICATED WORLDWIDE
** ALSO CONTROLLABLE BY MOSQUITO VECTOR ELIMINATION
even as the great epidemic infectious diseases have been 
conquered, new diseases have emerged, in every case requiring 
increasing expertise and more complex technological resources 
than ever imagined
In the most striking example of all, one agent of disease, 
smallpox virus, which at one time was the cause of about 
20 percent of all deaths in the world, has been eradicated 
from the face of the earth. This certainly has been one of 
the greatest achievements in the history of human 
civilization.
Even as the great epidemic 
infectious diseases have been 
conquered, at least in the 
United States and other devel­
oped countries, new diseases 
have emerged, in every case 
requiring increasing expertise 
and more complex technologi­
cal resources than ever 
imagined when diseases like 
smallpox were the target of 
prevention and control efforts. 
Today, human immunodefi­
ciency virus (HIV) infection 
and AIDS may be the best 
example of the need for ad­
vanced expertise, technology, 
equipment, and facilities— the 
best example of the need for a 
revolution in prevention and 
control strategies. There are 
many other diseases equally 
worthy of national attention, 
each requiring an integration 
of advanced laboratory and 
field investigative approaches, 
each requiring an integration 
of surveillance, reference diag­
nosis services, training and 
consultation, and applied 
research.
110R36
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A  CEN TU RY O F D ISCO VERY— THE SCIEN TIFIC BASIS FO R THE  
P R EV EN TIO N  A N D  CO N TRO L O F IN FEC TIO U S D ISEASES
against smallpox; Semmelweis 
and Holmes, who in the 1840s 
developed practical methods 
of cleanliness and disinfection 
in hospitals; Davaine, who in 
1850 first associated an infec­
tious organism, the anthrax 
bacillus, with disease; and 
Darwin, Wallace, and Mendel, 
who from 1859 onward revolu­
tionized thinking in genetics 
and evolution.
Upon this foundation, Pasteur 
established the microbiologic/ 
infectious disease sciences, 
first in 1857 by discovering the 
specificity of microbial fer­
mentations, then in 1865 by ex­
tending this concept to dis­
eases of silkworms, and fi­
nally between 1877 and 1895 
by extending the concept to 
animal and human diseases. 
His early work with patho­
genic bacteria centered on 
septic war wounds; he then 
turned to anthrax, several 
other bacterial diseases, and 
lastly to the viral disease, 
rabies. In each instance, he 
moved quickly from studies 
aimed at discovering the 
causative agent to the develop­
ment of specific immuniza­
tion. In 1885, Pasteur gave the 
first rabies vaccine to a little 
boy bitten severely by a rabid 
dog—that day marks the open­
ing of the modern era of infec­
tious disease research aimed at 
disease prevention and 
control. Clearly, Pasteur 
deserves his title of father of 
the microbiologic/infectious 
disease sciences.
culture of bacteria from 
clinical mixed flora and dis­
covering important bacterial 
pathogens, such as the causa­
tive agents of tuberculosis and 
cholera. As a result of the 
work of Pasteur and Koch, iso­
lation and identification of the 
causative agents of many 
important bacterial diseases 
proceeded at breakneck pace 
around the turn of this cen­
tury. Another class of microor­
ganisms, the rickettsiae, was 
added to the list by Ricketts, 
who in 1909 isolated the 
causative agent of Rocky 
Mountain spotted fever.
Pasteur was followed by Koch, 
who contributed much to bac­
tériologie laboratory methods, 
developing methods for pure
As this work proceeded, it 
became possible to consider 
the natural history and trans­
mission of the bacterial patho­
gens. Direct transmission by 
contact with contaminated 
common objects had been rec­
ognized empirically from 
ancient times—it was substan­
tiated in early laboratory 
studies of diseases such as 
childbirth bacterial sepsis, 
scarlet fever, and diphtheria, 
and led to concepts of cleanli­
ness, disinfection, isolation, 
and quarantine. The recogni­
tion of contamination of water 
supplies by the etiologic 
agents of diseases, such as 
typhoid fever, cholera, and 
dysentery, led to the develop­
ment of sanitary water and 
sewage systems and to the de­
velopment of public health 
regulations and institutions 
for their enforcement. The rec­
ognition of foodborne dis­
eases, such as tuberculosis, 
salmonellosis, and brucellosis, 
led to the pasteurization of 
milk, the sterilization of pro­
cessed food products, and also
The foundation for the microbiologic/ 
infectious disease sciences predates 
the concept of specificity of infectious 
disease causation. There are great 
names and discoveries to be remem­
bered: Hippocrates, the Greek physi­
cian and father of medicine, who in 
the fourth century B.C. made impor­
tant epidemiologic observations on 
infectious diseases; Fracastoro, who 
theorized in 1546 that epidemic dis­
eases were disseminated by minute 
particles carried over long distances; 
van Leeuwenhoek, who in 1676 first 
saw bacteria in his microscope; 
Hunter, who in 1767 while studying 
the nature of infection suffered an ill- 
fated self-inoculation of the syphilis 
organism; Spallanzani, who in 1775 
first grew bacteria in culture; Jenner, 
who in 1796 introduced vaccination
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to further development of regulatory 
systems. Discovery of silent carriers of 
certain bacterial pathogens as the 
source of contagion in some food- and 
waterborne disease episodes further 
advanced this development.
That some diseases are transmitted 
sexually was known from antiquity; 
sexually transmitted diseases were 
also the subject of the first public 
health programs aimed at the interrup­
tion of transmission. It had also been 
known from antiquity that some dis­
eases are transmitted from animals to 
humans (the zoonotic diseases); some 
of these diseases, for example anthrax, 
were among the first to be studied in 
laboratories. Finally, it was recognized 
that some of the most deadly diseases 
are caused by agents transmitted to 
humans from arthropods—plague, 
transmitted by rat fleas, typhus, trans­
mitted by lice, and many tropical dis­
eases, transmitted by mosquitoes and 
biting flies. Early laboratory and field 
work on arthropods and the organ­
isms they transmit led to the applica­
tion of vector control strategies for 
disease control.
The foundations of parasitology, 
immunology, virology, and epidemiol­
ogy were also established in this same 
era and became intertwined with the 
advance of bacteriology and mycology.
In the field of parasitology there are 
great names and discoveries to be re­
membered: Bilharz, who in 1851 dis­
covered the parasitic agent of schis­
tosomiasis; Manson, who in 1877 
demonstrated the mosquito transmis­
sion of filariasis; Laveran, who in 1880 
identified malaria parasites in human 
blood; and Bruce, who in 1894 traced 
the transmission of trypanosomiasis to 
the tsetse fly.
In the field of immunology and 
diagnostics, foundations were estab­
lished by: Metchnikoff, Bordet, and 
Ehrlich, who by discoveries made 
between 1883 and 1909, founded the 
science of immunology; Loeffler, Roux, 
Yersin, and Behring, who in 1888 dis­
covered bacterial toxins and antitoxins;
over the past forty years, outstanding scientists 
at the Centers for Disease Control have contributed 
substantially to the march of progress toward the 
prevention and control of infectious diseases
Avery and Lancefield, who between 1928 and 1933 developed 
the basic concepts of infectious disease diagnostics; Porter, 
Edelman, and Nisonoff, who in 1959 described the structure 
and function of antibodies; Jerne, who in 1974 conceived the 
network organization of the immune system; and Kohler and 
Milstein, who in 1975 developed the first monoclonal anti­
bodies.
In the field of virology great early names and discoveries to be 
remembered include Beijerinck and Ivanovsky, who in 1898 
discovered the first virus; Reed and Carroll, who in 1901 
isolated the first human viral pathogen, yellow fever virus; 
Andrewes, Laidlaw, Smith, and Burnet, who in 1933 first 
isolated influenza virus, just 15 years after the great influenza 
pandemic of 1918-19 in which 21 million people died; Blum- 
berg, who in 1963 discovered the "Australia antigen," thereby 
opening the modern era of viral hepatitis research; and Barre- 
Sinoussi, Montagnier, and their colleagues, who in 1983 dis­
covered human immunodeficiency virus (HIV), and, along 
with Gallo and his colleagues, demonstrated it to be the 
etiologic agent of AIDS.
In the field of therapeutics, wonderful discoveries were initi­
ated by Fleming, who in 1929 discovered penicillin; Waksman, 
who in 1940 discovered streptomycin; Florey, who in 1941 de­
veloped the methods for production and clinical application
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of penicillin; and Elion and Hitchings, who in 
1988 were awarded the Nobel Prize for Physi­
ology in Medicine for pioneering development 
of a number of important drugs for the treat­
ment of bacterial, viral, and parasitic disease. 
In the field of vaccinology, a seminal break­
through was made by Enders, Weller, and Rob­
bins, who in 1949 developed cell culture 
methods which are now used in most viral vac­
cine production systems.
In the field of epidemiology, fundamental dis­
coveries were made by Snow, the father of 
modern epidemiology, who in 1849 developed 
the methods of modem epidemiology while 
studying the source of a cholera epidemic at 
the Broad Street pump in London; Budd, who 
in 1873 described the epidemiologic features of 
typhoid fever; Panum, who in the 1870s out­
lined the epidemiology of measles; and Farr, 
who in 1885 advanced the use of vital statistics 
for understanding the epidemiology of infec­
tious diseases.
in the 1960s developed many fluorescent antibody 
diagnostic systems for bacterial diseases; Work, 
Chamberlain, and Sudia, who in the 1960s defined 
the distribution of the pathogenic arboviruses in the 
United States; Dowdle and colleagues, who in 1967 
distinguished herpes simplex virus strains that 
cause fever-blisters from those that cause genital 
disease; and Foege, Hopkins, Nakano, and many 
others, who during the 1960s and 1970s contributed 
greatly to field and laboratory aspects of the World 
Health Organization Smallpox Eradication Program. 
The accomplishments of these and many other scien­
tists must be seen as revolutionary.
Over the past forty-five years, outstanding sci­
entists at the Centers for Disease Control con­
tributed substantially to the march of progress 
in infectious disease prevention and control: 
Langmuir, who in 1951 established the first na­
tional epidemiology training program, the Epi­
demic Intelligence Service, and integrated this 
into a national field-based investigative epi­
demiology program; Edwards and Ewing, who 
in the 1950s and 1960s differentiated many of 
the pathogenic enteric bacteria; Kissling, who 
in 1958 developed rabies diagnostic methods 
and cell culture methods for vaccine produc­
tion; Shepard, who in 1960 adapted the causa­
tive bacillus of leprosy to an experimental 
animal model, thereby opening antileprosy 
antibiotic and drug development; Cherry, who
The opening of the science of molecular 
biology and its intertwining with the microbi- 
ologic/infectious disease sciences calls to mind 
other great names and discoveries: Avery, 
Hershey, and Chase, who between 1944 and 
1952 used bacteria and bacteriophages to dis­
cover that DNA carries all hereditary specific­
ity; Watson, Crick, and Wilkins, who in 1953 
discovered the structure of DNA and thereby 
the molecular basis for hereditary specificity; 
Nierenberg, Ochoa, Matthaei, Khorana, and 
others, who between 1961 and 1966 deciphered 
the genetic code; and Cohen and Boyer, who in 
1973 carried out the first experiments in 
genetic engineering;.
infectious diseases represent paramount 
health problems in developing countries; 
among these, none is more 
important than malaria
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INTO THE 1990s: THE M ED IC A L M ICR O BIO LO G IC/ 
IN FECTIO U S D ISEA SE SCIEN CES O F TO DAY
The revolution in the medical 
m icrobiologic/infectious disease 
sciences continues today at an 
ever-increasing pace and scale. We 
are in the midst of significant 
change in all aspects of medical 
bacteriology, virology, mycology, 
parasitology, and clinical infec­
tious disease sciences.
There is a revolution in 
epidemiologic investigative 
approaches. This is evidenced in 
the sophistication and scale of epi­
demiologic studies. It was such an 
epidemiologic investigative pro­
gram that led to the identification 
of aspirin use during febrile infec­
tions as a risk factor for Reye syn­
drome; this in turn led to actions 
that have resulted in a marked de­
crease in the incidence of the syn­
drome in the past few years. It was 
a similar epidemiologic inves­
tigative program that unveiled the 
emerging AIDS epidemic after a 
cluster of cases of Pneumocystis 
carinii pneumonia was recognized 
in Los Angeles in 1981. The revolu­
tion is also evidenced in the na­
tional A ID S/H IV  surveillance sys­
tem, the national salmonellosis sur­
veillance system, the national food- 
borne disease surveillance system, 
the national Lyme disease surveil­
lance system, the national hepatitis 
(sentinel counties) surveillance 
system, the national/international 
influenza surveillance system, and 
many other surveillance systems.
There is a revolution in the 
computer science underpinning of 
epidemiologic investigative work. 
Epidemiologists are increasingly 
using computer-based surveillance
techniques and new sources of
data for determining incidence epidemiologists and
trends of important infectious dis- statisticians are
eases. Sophisticated computer- increasingly using
based analytic techniques are computer-based
being used to characterize epi- surveillance
demic and endemic diseases, to techniques for
identify new disease problems, determining
and to expand knowledge of the incidence trends of
impact of long-term sequelae of important
acute infections. For example, in- infectious diseases
novative microcomputer-based 
approaches are being used in the 
development of hospital-based
surveillance of nosocomial infections via the National Noso­
comial Infections Surveillance system, and in the analysis of 
State health department laboratory data on several important 
infectious disease problems.
There is rapid progress occurring in computer networking in 
support of national surveillance systems and epidemiologic 
and laboratory research activities; this includes interconnec­
tions between the Centers for Disease Control and State, 
territorial, and city health departments, and other institu­
tions.
There is a revolution in the statistical science underpinning 
of infectious disease field and laboratory investigations. The 
demand for statistical validity to drive public health actions 
and expenditures involves sound development of protocols 
and sound data collection, analysis, and interpretation. 
Statistical models are used to project the future incidence of
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disease in populations, using methods ranging 
from empirical extrapolation of past trends to 
the construction of mathematical models of 
future trends.
There is a revolution in the approaches used to 
discover and identify new etiologic agents.
There are still important diseases with no 
proven causative agent, and there are important 
new diseases requiring etiologic searching and 
identification. In these cases, it seems that con­
ventional approaches are dispatched quickly, 
but when they fail, there is an ever-increasing 
complexity in the approaches then tried. The de­
termination and insight of the investigator in the 
field and in the laboratory are still key, but the 
tools used in the search are today most often 
products of modern biotechnology. For ex­
ample, in 1977 the cause of Legionnaires' dis­
ease, the bacterium Legionella pneumophila, was 
discovered by integrated field epidemiologic
the application of recombinant-DNA 
technology provides a new standard of quality 
of diagnostic reagents
investigation and innovative use of an experi­
mental animal model system. In 1978 the cause 
of toxic shock syndrome, the bacterium Staphylo­
coccus aureus, was recognized by innovative epi­
demiologic and laboratory investigative 
approaches. In 1983 the cause of AIDS, HIV, was 
discovered by insightful clinical and epidemiol­
ogic investigative approaches and very sophisti­
cated cell culture systems and molecular bio­
logic assays. Similar integration of field and 
laboratory approaches led to the discovery in 
1987 of a very fastidious new human herpes­
virus, the cause of a common childhood disease, 
roseola infantum. Quite recently the same 
integrated approach was used in the identifica­
tion of four genera of microsporidia as impor­
tant causes of diarrhea and wasting in patients 
infected with HIV.
There is a revolution in diagnostic technology, 
stemming from monoclonal antibody technol­
ogy and furthered by innovative equipment 
design. For example, diagnostic testing instru­
ments are now interfaced with microcomputers 
to automatically collect an d /or digitize informa­
tion and make it instantly available for tabula­
tion and analysis. Changes in the appearance of 
diagnostic laboratories are amazing— many now 
represent a view of the future, but changes in 
the future will be even more dramatic, and even 
more supportive of new epidemiologic ap­
proaches.
There is a revolution in the practical application 
of genetic engineering (recombinant-DNA tech­
nology), providing us with a new standard of 
quality of diagnostic antigens and reagents, and 
new kinds of vaccines and antimicrobial agents. 
DNA sequencing, molecular modeling, and syn­
thesis procedures employ amazingly sophisti­
cated equipment, as well as powerful computer 
software and national database networking.
The excitement of medical bacteriology, 
virology, mycology, parasitology, epidemiology, 
and clinical infectious disease sciences today is 
reflected in everything from the awarding of 
Nobel Prizes, to the growth of national and 
international m icrobiologic/infectious disease 
scientific meetings and congresses, to expanding 
press and media coverage of infectious disease 
issues and achievements.
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BEYO N D  THE YEAR 2000: THE LO N G -TER M  FU TU R E O F THE  
M ED IC A L M IC R O BIO LO G IC  / IN FECTIO U S D ISEA SE SCIEN CES
Despite a century of progress, the remaining infectious 
disease problems are awesome— the programs of the 
Center for Infectious Diseases reflect current priorities for 
addressing these problems. These programs also reflect 
the unique approach to disease prevention and control 
developed by the Centers for Disease Control over the 
past 45 years. There is a most significant list of new prob­
lems which will, in time, be addressed with more and 
more program resources. New directions for the pro­
grams of the Center for Infectious Diseases will reflect the 
fact that the world's medical micro­
biologists and infectious disease 
specialists are just beginning to turn 
their attention to the role of 
infectious agents in the many cate­
gories of chronic-persistent, degen­
erative, neurologic, oncogenic, 
immunopathologic, teratogenic, 
and other emerging disease issues.
NEUROLOGIC DISEASES: Many 
bacteria, viruses, fungi, and proto­
zoa infect the brain and spinal cord 
and cause acute damage; because 
neural tissues have such poor
microbiologists 
are turning their 
attention to the 
role of infectious 
agents in the 
many categories 
of chronic, 
degenerative, and 
newly emerging 
diseases
capacity to repair acute damage, long­
term neurologic sequelae are all too 
common. For example, bacterial 
meningitis caused by Haemophilus influ­
enzae type b, meningococci, and pneu­
mococci often leads to permanent neu­
rologic damage. Viral encephalitis, 
caused by measles virus, poliovirus, 
and the arthropod-borne encephalitis 
viruses, leads to much permanent neu­
rologic impairment in children in de­
veloping countries. Yet other infectious 
agents lead to fatal neurologic disease: 
HIV dementia, rabies, Creutzfeldt- 
Jakob disease, subacute sclerosing pan­
encephalitis, progressive multifocal 
leukoencephalopathy. Finally, there is 
a growing body of evidence that many 
neurologic diseases, such as Alz­
heimer's disease, amyotrophic lateral 
sclerosis, multiple sclerosis, and trans­
verse myelitis, may be caused by infec­
tious agents, either directly or indi­
rectly via triggering of aberrant cellular 
changes.
ONCOGENIC DISEASES: Infectious 
agents cause cancers in humans, either 
by direct or indirect means. Cancers 
proven to be caused by viruses, such 
as those caused by hepatitis B virus 
(primary hepatocellular carcinoma—  
the most common cancer in the 
world), human papillomaviruses 
(cervical cancer), EB virus (nasophar­
yngeal cancer, B-cell lymphomas), 
HTLV-I (adult T-cell lymphoma), and 
HIV (possibly the trigger of lympho­
mas), beg the question whether other 
cancers are also caused by infectious 
agents. There is a need for additional 
investigation of other infections 
wherein the persistent presence of in­
fectious agents in the individual may 
be the cause of cancers years after the
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primary infection. In the future it is clear that more and 
more cancers of humans will be found to have infectious 
etiologies or triggering cofactors.
IMMUNOPATHOLOGIC DISEASES (DISEASES 
CAUSED BY AN ABERRANT IMMUNE RESPONSE): 
Infectious agents can trigger autoimmune reactivity 
against the tissues of the infected patient; the classic 
example is rheumatic heart disease, where antibodies eli­
cited against streptococcal proteins during acute infection 
then cross-react with normal proteins of heart muscle 
cells, causing severe damage. The same antibodies can 
also cause glomerulonephritis. Other autoimmune 
diseases which may be triggered by infectious processes 
include Guillain-Barre syndrome, Reiter's syndrome, and 
psoriasis.
TERATOGENIC DISEASES (DISEASES CAUSING 
FETAL/N EW BORN  DAMAGE OR DYSFUNCTION): 
Infection of pregnant women can on occasion lead to in­
fection of the fetus or the newborn. Because of the imma­
ture state of the immune system of the fetus and new­
born, such infections can be severe and the cause of per­
manent damage. The classic example is the fetal rubella 
syndrome, which is entirely prevent­
able by prior maternal vaccination.
Other infectious agents that may 
affect the fetus include Treponema 
pallidum, human parvovirus B19, 
herpes simplex virus, 
cytomegalovirus, HIV, and 
toxoplasma.
leadership role in surveillance, 
epidemiologic investigations, labora­
tory reference diagnosis, and the 
development of prevention guidelines; 
(d) infections acquired in hospitals, 
for example, life-threatening infections 
acquired in intensive care units, where 
the Center for Infectious Diseases has 
the national leadership role in 
surveillance, epidemiologic investiga­
tions, and the development of preven­
tion guidelines; (e) foodborne diseases 
associated with modern food indus­
tries, for example, Salmonella enteritidis 
infections associated with eggs and 
Listeria monocytogenes infections asso­
ciated with a variety of food products, 
where the Center for Infectious Dis­
eases has the national leadership role 
in surveillance and epidemiologic in­
vestigations and plays a major role 
along with other agencies in the devel­
opment of prevention strategies;
(f) hepatitis C infection, newly
despite a century of progress, the remaining infections 
disease problems are awesome— the programs of the 
Center for Infectious Diseases reflect current priorities for 
addressing these problems
MAJOR EMERGING AND CHANG­
ING INFECTIOUS DISEASE PROB­
LEMS: Other emerging and changing 
infectious disease problems include:
(a) infections associated with child 
care, where the Center for Infectious 
Diseases has the national leadership 
role in surveillance, research, and de­
velopment of prevention guidelines;
(b) infectious diarrhea in children, 
especially fatal diarrhea dispropor­
tionately affecting minorities, where 
the Center for Infectious Diseases 
has the national leadership role in 
epidemiologic investigations that 
will lead to new prevention strate­
gies; (c) influenza and pneumococ­
cal pneumonia, which are important 
causes of death in older people, 
where the Center for Infectious Dis­
eases has the national
recognized as an important cause of chronic liver dis­
ease, where the Center for Infectious Diseases has the 
national leadership role in surveillance and research 
that will lead to the development of prevention 
guidelines; (g) Lyme disease, which is increasing in 
incidence explosively in many parts of our country, 
where the Center for Infectious Diseases has the na­
tional leadership role in surveillance, epidemiologic 
investigations, and the development of vector control 
guidelines, and where a major new research program 
will lead to national prevention guidelines;
(h) diseases caused by very dangerous microorgan­
isms such as Lassa fever virus, where the Center for 
Infectious Diseases has national responsibility for 
providing specialized expertise and maximum con­
tainment laboratory facilities, as well as overseas 
field investigative programs; and (i) major tropical 
diseases, including malaria, dengue, and polio, 
which represent a devastating burden principally in 
developing countries, where the Center for Infectious 
Diseases has national responsibility for providing 
specialized expertise and laboratory reference diag­
nostic services, as well as overseas field investigative 
programs.
the Center for Infectious Diseases provides 
specialized expertise and laboratory 
reference diagnostic services for many field 
investigative programs
THE CENTERS FO R  D ISEA SE CO N TRO L AN D  
THE CENTER FO R IN FECTIO U S D ISEASES
The Centers for Disease Control is the agency of the United 
States Department of Health and Human Services /  Public 
Health Service responsible for leading national efforts to pro­
mote health and prevent disease, disabilities, and premature 
death. Working with State and local health departments, other 
Federal agencies, and other organizations and individuals, the 
staff of the Centers for Disease Control carries out programs 
aimed at understanding the causes of diseases and developing 
the means of preventing them.
Major units of the Centers for Disease Control are 
concerned with chronic diseases, injury, diseases 
associated with environmental, home, and 
workplace hazards, and diseases associated with 
controllable risk factors, such as poor nutrition, 
smoking, lack of exercise, high blood pressure, 
stress, and drug misuse. Headquarters of the 
Centers for Disease Control is in Atlanta, Geor­
gia, but other facilities are located throughout the 
United States and in several other countries. The 
Centers for Disease Control has a staff of about
6,000 working in 170 different fields of science 
and public administration.
The Centers for Disease Control had its 
beginnings in the Office of Malaria Control in 
War Areas. This Office originated in 1946 and 
was located in Atlanta because of the prevalence 
of malaria in the Southeast. The first staff repre­
sented specialists in the diagnosis, prevention, 
and control of such diseases as malaria, dengue, 
schistosomiasis, filariasis, Japanese encephalitis, 
and other diseases of the Pacific war zone. The 
original organization soon became the Commu­
nicable Disease Center, and in 1967 it became the 
National Communicable Disease Center. In 1970 
the name was changed to the Center for Disease
Control and in 1980 to the Centers for Disease 
Control— many names, but always the same 
initials. The Centers for Disease Control is now 
organized into five Centers (the Center for 
Chronic Disease Prevention and Health Pro­
motion, the Center for Environmental Health 
and Injury Control, the Center for Prevention 
Services, the National Center for Health Statis­
tics, and the Center for Infectious Diseases), 
one Institute (the National Institute for Occu­
pational Safety and Health), and three Pro­
gram Offices (the Epidemiology Program 
Office, the International Health Program 
Office, and the Public Health Practices Pro­
gram Office).
Today, responsibility for the prevention and 
control of infectious diseases is focused in the 
Center for Infectious Diseases and also in­
volves the Center for Prevention Services (par­
ticularly in the areas of sexually transmitted 
diseases, tuberculosis, and vaccine-prevent­
able diseases). The Center for Infectious 
Diseases was created in 1981 by the merger of 
components of the former Bureau of Epidemi­
ology and the Bureau of Laboratories.
emerging and changing problems of the 1990s include infections associated with child 
care, infectious diarrheas of children, influenza and pneumococcal pneumonia in older 
people, infections acquired in hospitals, foodbome infections, hepatitis C, Lyme disease,
and others that are equally challenging
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THE M ISSIO N  O F THE CENTER FO R IN FECTIO U S D ISEASES
The mission of the Center for Infectious Diseases is to prevent 
unnecessary illness and death caused by infectious diseases in 
this country and around the world.
The Center accomplishes its mission through:
• Epidemic assistance
• Epidemiologic investigations and field studies
• Surveillance
• Etiologic agent reference identification
• Reference diagnostics and reagent services
• Education, training, and consultation
• Technology transfer
• Cooperation, coordination, and collaboration with other
units of CDC, other Federal agencies, State and local 
health departments, international health agencies, 
academic institutions, and public, private, and 
voluntary organizations
• Formulation, dissemination, and evaluation of
prevention strategies
• Applied epidemiologic and laboratory research:
• Characterization of etiologic agents
• Diagnostics development and evaluation
• Vaccine development and evaluation
• Applications of biotechnology and molecular biology
• Immunology and pathogenesis of infectious diseases
• Antimicrobial drug resistance
• Identification of reservoirs and modes of transmission
of disease agents
• Identification of disease vectors
• Characterization of dangerous pathogens
• Prevention and control strategies
Pseudomonas aeruginosa, scanning electron micrograph, 
magnification x20,000 — this bacterium is an important cause of 
bronchopneumonia, septicemia, meningitis, and urinary tract 
infection, especially in patients with lowered resistance
The Center operates in all 
bactériologie, virologie, parasi­
tologic, mycologic, epidemiol­
ogic, and clinical infectious 
disease disciplines, and in 
several interdisciplinary areas 
including:
• Opportunistic infectious
diseases in HIV-
infected patients
• Infectious diseases in out-
of-home child-care
settings
• Foodborne and
waterborne diseases
• Tropical infectious
diseases
• Chronic infectious
diseases
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FACILITIES FO R R ESEA R CH  A N D  SERVICE
the CDC Viral / Rickettsial Diseases 
Laboratory, opened in 1988, represents the 
best of modem biocontainment design and 
construction
The principal facilities of the Center for Infectious Dis­
eases are located in Atlanta (at Clifton Road, Executive 
Park, Chamblee, and Lawrenceville). Facilities are also 
located in Fort Collins, Colorado; Anchorage, Alaska; 
and San Juan, Puerto Rico. Staff members are also 
assigned to some State and local 
health departments in the 
United States and to public 
health units in several other 
countries (Guatemala, Sierra 
Leone, Cote d'Ivoire, Zaire,
Kenya, and the World Health 
Organization headquarters in 
Switzerland).
staff. This facility houses equipment 
and instruments such as oligonucleotide 
synthesizers, automated nucleic acid se­
quencers, peptide sequencers, high 
performance liquid chromatography 
systems, and specially modified auto­
mated thermocyclers for the next gen­
eration of development of polymerase 
chain reaction technology and other 
microbial gene amplification technolo­
gies.
The Center for Infectious Diseases' 
newest facility is the Viral/Rickettsial 
Diseases Laboratory, opened in 1988; 
this facility represents the best of mod­
ern biocontainment design and con­
struction. The requirements for a M axi­
mum Containment Laboratory (Bio­
safety Level 4 laboratory) are so com­
plex and demanding of engineering and 
laboratory staff expertise that there are 
only two facilities in the United States, 
one at the Centers for Disease Control
Center for Infectious Diseases
Locations
Facilities include offices and as­
sociated facilities for computer 
and data management equip­
ment, general microbiologic 
laboratories, and highly special­
ized laboratories that provide 
for biocontainment and safe use 
of radioisotopes and toxic 
chemicals. The Center has 
developed a Biotechnology 
Core Facility to support pro­
grams with the latest "high 
tech" equipment and an expert
â t f
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and the other at Fort Detrick (U.S. 
Army), and only a few others else­
where in the world. The staff 
member wears a full-body pressur­
ized "space suit" connected by hose 
to a breathing air system. Entry into 
and exit from the laboratory are 
through an air-lock system, the exit 
after a chemical shower in a chamber 
where the exterior of the "space suit" 
is thoroughly decontaminated. 
Within the laboratory, work with 
infectious organisms is carried out 
using all the same kinds of biocon­
tainment equipment, such as bio­
safety cabinets, and all the same 
kinds of safe practices and proce­
dures as are used in other laborato­
ries. All in all, this laboratory repre­
sents the ultimate in laboratory fa­
cilities and operations design for the 
protection of the laboratory staff and 
the environment from pathogens.
The facilities of the Center for Infec­
tious Diseases are operated in accord 
with national biosafety standards for 
microbiologic and biomedical labo­
ratory operations. These standards 
are set under the auspices of the 
Centers for Disease Control and the 
National Institutes of Health. Work 
with organisms not known to cause 
disease is done at Biosafety Level 1 
(BSL 1), and work with organisms 
that represent only a modest risk, 
such as viruses that cause the com­
mon cold and bacteria that cause 
diarrhea, is done at BSL 2. Work 
with organisms that can cause ser­
ious disease, but for which vaccines 
or antibiotics are available, such as 
the tuberculosis bacillus, rabies 
virus, and the rickettsia that causes 
Rocky Mountain spotted fever, is 
done at BSL 3. Work with organisms 
that pose a high risk of life- 
threatening disease and for which no 
vaccines or antibiotics are available, 
such as the viruses that cause hem­
orrhagic fever and encephalitis, is 
done at BSL 4 (the Maximum Con­
tainment Laboratory).
at Biosafety Level 4 the staff member wears a full-body 
pressurized "space suit" connected by hose to a breathing 
air system—exit from the laboratory is through an air­
lock system and a chemical shower
m m
c :> ,. /
/
the facilities of the 
Center for Infectious 
Diseases are 
operated in accord 
with national 
biosafety standards 
for microbiological 
and biomedical 
laboratory 
operations
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THE STAFF O F THE CENTER FO R IN FECTIO U S D ISEASES
The key to programmatic and institutional 
development within the Center for Infectious 
Diseases is its staff— the Center for Infectious 
Diseases has a remarkable staff, dedicated and 
nationally and internationally renowned. Evi­
dences of distinction of the professional staff in­
clude receipt of many national and international 
awards, leadership in many professional socie­
ties, publication of many significant papers, and 
election to many editorial and professional 
boards and committees. Many members of the 
professional staff are involved in education and 
training, most notably in advanced technical 
training and disease investigation training 
(especially in concert with the World Health
Organization and other international agencies). 
Many staff members are also involved in formal 
teaching through university affiliations. It is 
clear that as the generations follow one another, 
the staff of the Center for Infectious Diseases 
keeps getting better and better. The newest 
members of the staff are outstanding— although 
these staff members could have chosen other 
employment opportunities, they have chosen 
the Center for Infectious Diseases and the Cen­
ters for Disease Control because of the unique 
opportunity offered to combine scientific and 
public service activities for the betterment of the 
health of the people of the United States and the 
rest of the world.
the staff of the Center for Infectious Diseases 
integrates the many fields of the medical 
microbiologic /  infectious diseases sciences
the integration of epidemiologic, laboratory, 
and statistical sciences allows comprehensive 
assessment of complex disease problems
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A  SAM PLIN G  O F PRO G RAM S, PRO JECTS , A N D  A C TIVITIES  
O F THE CENTER FO R IN FECTIO U S D ISEASES
The following are but some examples of the programs, projects, 
and activities being carried out in the Center for Infectious Dis­
eases at this time. These examples have been chosen to reflect the 
breadth of the overall program of research and service, and the 
programmatic depth, technologic complexity, and demand for 
staff expertise and energy that are called for in efforts to solve 
today's infectious disease problems.
H U M A N  IM M U N O D EFIC IEN C Y V IRU S IN FECTIO N S AND  
A ID S: HIV infection and AIDS are the most important infectious 
disease problems in the United States today. By the end of 1989, 
more than 100,000 cases of AIDS had been reported, more than
30,000 cases in 1989 alone. These numbers will continue to 
increase in the next few years as many of the one million persons 
who are infected in the United States develop AIDS. The goal of 
the HIV /  AIDS program is to define and test means for the pre­
vention and control of virus transmission: this involves 
definition of the epidemiology and natural history of HIV infec­
tion and identification of population groups at risk. This is 
accomplished through AIDS case surveillance, HIV serosurveil- 
lance, and domestic and international epidemiologic and labora­
tory investigations. The national HIV seroprevalence survey 
system involves over 30 metropolitan areas and selected popula­
tions including military recruits, blood donors, clinic patients, 
intravenous drug users, childbearing women, Job Corps appli­
cants, prisoners, and college students. Sentinel hospital-based 
surveillance is also being used to determine trends. Epidemiol­
ogic studies are focused on homosexual men, IV drug users,
the dynamics of the AIDS epidemic in the United States to 
date, and the projected number of cases in the future
persons with hemophilia, per­
sons with transfusion-associated 
disease, female prostitutes, sex 
partners of persons with AIDS or 
at increased risk for AIDS, babies 
born of infected mothers, health­
care workers, and long-term sur­
vivors. International collabora­
tion involves studies in Zaire, 
Cote d'Ivoire, and Thailand and 
includes epidemiologic and labo­
ratory studies on HIV-1 and 
HIV-2.
O PPO RTU N ISTIC  
IN FECTIO N S IN H IV- 
IN FECTED  PA TIEN TS: Patients 
with AIDS develop certain op­
portunistic infections, such as 
Pneumocystis carinii pneumonia, 
Mycobacterium avium-intracellu- 
lare disease, and invasive can­
didiasis, that in the past were 
seen only in patients whose im­
munity was compromised by 
malignancies or medications. 
However, it has also become ap­
parent that other infections that 
have not traditionally been con­
sidered opportunistic, such as 
pneumococcal disease and sys­
temic salmonellosis and shigel­
losis, are occurring in HIV-in­
fected patients, often at rates 100- 
fold greater than expected. These 
infections often occur before 
manifestations of profound 
immunodeficiency; an example 
of this is pneumococcal bactere­
mia, which has been seen com­
monly in HIV-infected persons in 
San Francisco. Until prevention 
or control of HIV infection is 
possible, strategies for control 
and prevention of these oppor­
tunistic infections must be 
improved and implemented.
Reported and Predicted AIDS Cases 
United States
■  Diagnosed cases, adjusted for 
estimated reporting delays and 
Incomplete reporting
El Midpoint of predicted range 
for cases
Upper bound
Lower bound
198211983 11984119851198611987119881198911990119911199211993 
Date of Diagnosis 
Predictions were made using back-calculation and extrapolation from  recent trends, 
based on cases diagnosed through June 1989 and reported through September 1989.
HHS/PHS/CDC
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An interdisciplinary program is in place in the Center for 
Infectious Diseases with the aim of doing this. Epidemiol­
ogic studies of specific infections are being conducted to 
determine rates of disease in different populations infected 
with HIV. Laboratory studies are being conducted to im­
prove diagnostics. Such studies will lead to recommenda­
tions for better preventive and treatment regimens. As an 
example, studies of populations at risk for HIV infection 
(e.g., young men in certain geographic areas) have shown 
increased risk for shigella bacteremia; this information is 
being used to guide early diagnosis, long-term prophylac­
tic antibiotic therapy, and targeted preventive educational 
programs.
IN FECTIO N S IN H O SPITA L IN TEN SIV E CARE  
UN ITS: In the United States, hospital-acquired infections 
affect two million patients annually; direct extra patient 
care costs are approximately $3.5 billion. Infections in 
immunocompromised patients and in patients in intensive 
care units account for a large proportion of all infections. 
Programs of the Center for Infectious Diseases to reduce 
infection rates in intensive care units include the develop­
ment of surveillance systems, the assessment of infection 
trends and rates, the identification of risk factors for 
infection, and the development of preventive intervention 
strategies. The National Nosocomial Infections Surveil­
lance system is operated to provide data and to guide re­
commendations for intervention; through this program, 
patterns of infection can be detected at national, hospital, 
hospital unit (e.g., intensive care unit), procedure (e.g., 
intravascular catheter usage, coronary artery bypass sur­
gery), ward, or patient level. Using these data, guidelines 
for the prevention of specific infections (e.g., pneumonia, 
urinary infections) are being developed and implemented.
patients with AIDS develop debilitating opportunistic 
infections, such as pneumonia caused by Cryptococcus 
neoformans, as shown in this stained section of human 
lung obtained at autopsy
gene amplification technology (the 
polymerase chain reaction— PCR) 
allows the detection of very small 
amounts of DNA or RNA of 
infectious agents— it has made 
possible the detection of HIV 
infection early in the course of 
infection
Neonatal intensive care unit patients 
have one of the highest rates of 
hospital-acquired infection of any 
hospital population. It is estimated 
that approximately 9,000 infant 
deaths are caused by hospital-ac- 
quired infections annually. Studies 
are under way to evaluate infection 
risk for particular invasive proce­
dures used in neonatal intensive care 
units; studies are also focused on the 
utility of rapid diagnostic tests. For 
example, invasive candidiasis is the 
cause of serious illness and mortality 
in immunocompromised newborn 
patients. Epidemiologic and labora­
tory studies are determining the 
utility of a rapid diagnostic test that 
allows early diagnosis for guiding 
therapy.
there are 28 WHO 
Collaborating Centers for 
Reference and Research in the 
Center for Infectious Diseases
SU RG ICA L W O UN D  
IN FECTIO N S: Surgical wound 
infections account for approxi­
mately 30 percent of all hospital- 
acquired infections; these infec­
tions lead to prolonged hospital­
izations, increased hospital costs, 
and increased mortality. Many 
surgical wound infections can be 
prevented via the establishment in 
hospitals of an active infection 
surveillance and control program. 
For example, a surgical patient in­
fection risk index and a 
procedure-specific infection rate 
index can be used as parts of a 
system for evaluating the infec­
tion rate obtained by each sur­
geon. This kind of system, 
established via recommendations 
and training from the Center for 
Infectious Diseases, via its Na­
tional Nosocomial Infections 
Surveillance system, has been 
shown to substantially reduce the 
rate of surgical wound infections.
IN FECTIO U S D ISEA SES IN O U T-O F-H O M E CH ILD  
CARE: In recent years, shifts in the structure of the American 
family have resulted in dramatic changes in the care and 
rearing of young children. The proportion of children in out- 
of-home child care has increased substantially; currently, an 
estimated 11.6 million children spend a minimum of ten hours 
per week in out-of-home child care. The fastest growing sub­
group of working mothers are those with children under one 
year of age, with fully half of these women employed. This 
trend is likely to continue; by the year 2000 it is estimated that 
more than 75 percent of mothers with children under six years 
of age will be working outside the home. The economic 
impact of child-care-associated morbidity is great: working 
mothers are forced to miss one to four weeks per year to care 
for their sick children. Studies suggest that over 60 percent of 
employee absenteeism may be due to unmet child-care needs, 
particularly those of sick children. Infectious diseases are the 
most important causes of morbidity in child-care centers, with 
respiratory and diarrheal illnesses being most common. 
Depending on the disease, children attending out-of-home 
child care are estimated to have a 2- to 18-fold increased risk 
of becoming ill compared with children not attending a child­
care center. The most common diarrheal pathogens in children 
in out-of-home child care are Giardia lamblia, Shigella species, 
and rotavirus— agents spread by person-to-person contact.
The vast majority of respiratory infections in child-care centers 
are viral in nature, but otitis media and its sequelae are also 
common. Some infectious agents appear to be endemic in the 
child-care center setting: Giardia lamblia can become endemic, 
causing repeated cases of diarrhea. About 12-15 percent of all 
reported cases of hepatitis A have been associated with child­
care centers; the spread of hepatitis from children in child-care 
centers to family members and then to the community has be­
come an important problem. Nearly all states have regulations
W o r k i n g  M o t h e r s  of 
Ch i l d r e n  U n d e r  Six
shifts in the 
structure of 
the 
American 
family have 
residted in 
great 
increases in 
out-of-home 
child-care —  
this has led 
to increases 
in certain 
childhood 
infectious 
diseases
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the Center for Infectious Diseases, together with 
professional organizations, State and local health 
authorities, child-care providers, and parents' 
groups, is developing disease prevention guidelines 
for child-care centers
for the control of infectious diseases in licensed child-care 
centers; however, scientific data to support recommendations 
are lacking. Risk factors are not well understood; for ex­
ample, the management of ill children in child-care centers 
and the exclusion of sick children are subjects of great contro­
versy. Despite the importance of out-of-home child-care 
health issues to State and local health departments, resources 
are limited; many agencies need guidance in developing sys­
tems for prevention of infectious 
and vaccine-preventable 
diseases (injuries and environ­
mental hazards are also prob­
lems). The Center for Infectious 
Diseases is actively involved in 
epidemiologic studies to 
determine patterns of child-care 
utilization and in coordinating 
efforts to develop guidelines 
with State and local health au­
thorities, out-of-home child-care 
providers, and parents' groups.
National infection control guide­
lines, in the form of information 
kits, are being distributed 
widely. The Center for Infectious 
Diseases is also developing 
diagnostic tests for Giardia and 
respiratory and enteric viruses to 
facilitate disease control pro­
grams in these settings.
FO O D BO RN E AND W A T ER ­
BO RN E D ISEA SES: Recent public 
concern over foodborne disease is 
justified; there is evidence that dis­
ease incidence is increasing. Esti­
mates of disease incidence range 
from a few million to 80 million 
cases per year; comprehensive data 
are lacking, but it seems clear that 
the higher estimates are closest to 
reality. Foodborne disease results in 
over 9,000 deaths and more than $1 
billion in economic losses each year. 
Changes in animal husbandry prac­
tices, food processing, and the de­
velopment of more ready-to-eat 
food products have created new 
situations where pathogens are in­
troduced into foods. Changes in 
food distribution systems involving 
fewer but larger processors are in­
creasing the number of large, 
interstate outbreaks of disease. The 
Center for Infectious Diseases has 
identified a series of important 
emerging problems: grade A shell 
eggs harboring Salmonella enteritidis 
are causing epidemic foodborne 
disease in the northeastern United 
States, and the problem is spreading 
to other parts of the country;
the Center for Infectious Diseases, in cooperation 
with other agencies, is working to better identify 
important causes of foodborne disease and to develop 
rapid diagnostic tests for foodborne pathogens
processed foods contaminated with 
Listeria monocytogenes are causing 
over 1,600 illnesses and 400 deaths 
each year in pregnant women, their 
fetuses and newborn babies, the 
elderly, and persons with under­
lying diseases (recalls of products 
containing Listeria have cost mil­
lions of dollars in recent years); 
ground beef, contaminated with a 
newly recognized pathogenic strain 
of Escherichia coli, serotype 
0157:H 7, is causing many out­
breaks and sporadic cases of hem­
orrhagic diarrhea and hemolytic 
uremic syndrome (the most com­
mon cause of acute renal failure in 
children); and raw or undercooked 
shellfish are responsible for hepati­
tis, cholera, and Vibrio vulnificus in­
fections (the latter, although rare, 
can have a 50 percent mortality 
rate). There are other disturbing 
trends: Salmonella and Campylobacter 
infections are increasing steadily, 
nearly always in association with 
consumption of foods of animal 
origin. In 1985, a single dairy 
caused 200,000 cases of salmonel­
losis. Currently available data are 
too limited to lead to fully effective 
prevention and control programs. 
Specific foods that cause large 
numbers of illnesses can escape 
recognition, and critical control 
measures are not identified. To 
deal with these foodborne disease 
problems, the Center for Infectious 
Diseases, in cooperation with other 
Federal agencies, is instituting a 
program that will better identify 
important causes of foodborne 
disease, determining which foods 
are causing disease, developing 
rapid and accurate diagnostic tests 
for foodborne pathogens, and de­
termining strategies for the 
prevention of foodborne disease. 
This program will guide critical- 
control-point food inspection 
activities of regulatory agencies 
and will lead to more rapid public 
health response to outbreaks of 
foodborne disease.
G O N O RRH EA : Although the incidence of gonorrhea has 
been decreasing steadily since 1978, it is still the most com­
mon of the reportable infectious diseases in the United States 
(in 1988, 688,000 cases were reported to the Centers for Dis­
ease Control). Pelvic inflammatory disease and disseminated 
gonococcal infections may occur if uncomplicated infections 
are not treated. Pelvic inflammatory disease is the most im­
portant complication; it occurs in approximately 8 percent of 
women with gonorrhea, resulting in tubal damage and an in­
creased probability of subsequent ectopic pregnancy. It has 
been estimated that the direct cost of gonococcal pelvic 
inflammatory disease is $1.7 billion per year. The challenge of 
controlling gonorrhea remains formidable because of an 
increase in the proportion of Neisseria gonorrhoeae isolates 
resistant to currently used antimicrobial drugs. Penicillin- and 
tetracycline-resistant gonococcus strains have increased dra­
matically in the past few years, exceeding 20 percent of 
isolates in many areas. Studies are under way in the Center 
for Infectious Diseases to further define the magnitude and 
nature of this antimicrobial drug resistance and to develop 
guidelines for proper antimicrobial drug usage.
Antibiotic resistant isolates of 
Neisseria gonorrhoeae, *
United States, Fiscal Years 1984-1989
7.5 —i--------- --------------------------------------------------------------------------
1984 1985 1986 1987 1988 1989 
Fiscal Years
‘ >95% are PPNG.
SEXU A LLY TRA N SM ITTED  CH LAM YD IAL IN FECTION :
Chlamydial infection is not reportable, but there is good 
evidence that it is the most common sexually transmitted 
infection in the United States, exceeding the combined num­
ber of gonorrhea and syphilis infections. Three to five million 
cases of acute infection occur annually, leading to about
500,000 cases of pelvic inflammatory disease. The cost of 
treating chlamydial pelvic inflammatory disease exceeds $2 
billion annually. Sequelae following pelvic inflammatory dis­
ease include infertility and ectopic pregnancy. Infants born of
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infected mothers are exposed at 
birth and are at risk for 
chlamydial conjunctival infec­
tion and pneumonitis. Lack of 
awareness of the disease by 
both public and private sector 
health-care providers, together 
with the paucity of laboratories 
providing diagnostic testing, 
have hampered disease control 
efforts. Research on genital 
chlamydia infections in the Cen­
ter for Infectious Diseases 
includes collaborative efforts to 
identify populations at risk and 
to improve diagnosis.
PED IA TRIC  R ESPIR A TO RY  
D ISEA SE: Acute lower respira­
tory infection is the leading 
cause of death in children in the 
world. In developing countries, 
bacteria have been isolated from 
up to 92 percent of children 
with pneumonia; the most com­
mon pathogens are Streptococcus 
pneumoniae and Haemophilus 
influenzae. Viruses and bacteria 
are important causes of pneu­
monia in children in the United 
States; however, accurate inci­
dence data are not available, 
partly because sensitive and 
specific diagnostic tests are 
unavailable or not in wide­
spread use, and partly because 
antimicrobial drug treatment is 
too often started before appro­
priate specimens for bacterial 
culture are obtained. In one 
study of young children, 
Streptococcus pneumoniae was 
isolated from half of culture- 
confirmed bacterial pneumonias 
and Haemophilus influenzae type 
b from another third. The best 
estimate of the incidence of 
pneumococcal bacteremia in 
children under 2 years of age in 
the United States is 1.5 cases 
per 1,000 children per year. 
Pneumococcal bacteremia may 
be associated with pneumonia, 
especially in very young
children, and with otitis media. Improved methods for rapid 
diagnosis of pneumococcal disease, involving immunologic 
probes and other molecular biologic techniques, are under de­
velopment in the Center for Infectious Diseases. These methods 
are being integrated into prevention programs being developed 
in collaboration with others, nationally and internationally. For 
example, a large pneumococcal vaccine trial in infants (testing a 
protein-polysaccharide conjugate pneumococcal vaccine) is in 
preparation in The Gambia, where the incidence of pneumonia 
is very high; this trial will yield information on the epidemiology 
and etiology of lower respiratory infections, as well as on the ef­
ficacy of the vaccine, which 
will be immediately extend­
able to the United States and 
the rest of the world.
IN FLU EN ZA : Influenza 
remains the last great epi­
demic disease— it returns 
every winter to afflict people 
of all ages and from all walks 
of life. Influenza epidemics 
are responsible for spreading 
waves of work and school 
absences, physician office 
visits, hospitalizations, and 
deaths. About 10-20 percent 
of the population may be­
come ill during a single 
epidemic, resulting in direct 
costs of over $10 billion. The 
disease is particularly severe 
in the elderly and those with 
underlying diseases, causing 
an estimated 50,000 deaths 
per year. The chance of 
another great epidemic 
remains a concern: in the 
epidemic of 1918 more than
500,000 persons died in the United States alone. The Center for 
Infectious Diseases conducts epidemiologic and laboratory ac­
tivities directed at the control and prevention of influenza. A 
never-ending watch is kept on the occurrence of influenza 
worldwide and on the changing properties of virus isolates. 
Characterization of virus strains leads to the identification of 
new variants. Discovery of new variants, in turn, begins a chain 
of actions that ends with reformulation of vaccines. Each year 
there is a race against time to have the best vaccine available 
before a new variant arrives in the United States. During epi­
demic periods, the Center for Infectious Diseases conducts sur­
veillance to assist health-care providers in making decisions con­
cerning vaccine and antiviral drug use. Laboratory research is 
aimed at improving vaccines, monitoring antiviral drug resis­
tance, and developing rapid diagnostic tests.
a never-ending watch is 
kept on the changing 
genetic properties of 
influenza virus
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PN EU M O CO CCA L PN EU M O N IA  IN TH E ELD ERLY:
Pneumococcal pneumonia accounts for an estimated 150,000 to
500,000 cases and 50,000 deaths in the United States each year. 
Individuals with underlying diseases are more susceptible to se­
rious illness and death; over 40 percent of elderly persons with 
bacteremia may die of this illness, and patients with AIDS have a 
risk of bacteremia and death 100-fold greater than would be the 
case otherwise. Antimicrobial drugs have significantly decreased 
the mortality of pneumococcal pneumonia, yet the increasing in­
cidence of penicillin and multiple-drug-resistant strains of pneu­
mococci are an important concern. Through hospital-based
the Center for Infections Diseases is assessing the impact of 
vaccination against pneumococcal pneumonia— vaccine- 
based prevention strategies are being developed in 
collaboration with State and local health departments and 
academic institutions
studies, the Center for Infectious Diseases is examining the emer­
gence of antibiotic resistance, and is collaborating with other 
agencies and institutions in developing alternative approaches to 
therapy. Pneumococcal vaccines are available in the United States 
but are underutilized. The Center for Infectious Diseases is 
conducting a variety of epidemiologic and laboratory studies to 
measure the impact of vaccination on each serotype of pneumo­
cocci responsible for substantial disease. Vaccine-based preven­
tion strategies are being developed in collaboration with col­
leagues in State and local health departments and academia; the 
goal is to prevent disease, especially in high-risk populations. 
Parallel laboratory research activities, involving novel molecular 
biologic techniques, are aimed at developing rapid diagnostic 
tests for pneumococcal disease, so as to better guide vaccine 
usage and antibiotic therapy.
TU BER C U LO SIS: Tuberculo­
sis is often thought of as a 
global health problem centered 
in developing countries, but 
there are over 20,000 cases and
1,000 deaths each year in the 
United States. In 1989, tubercu­
losis was targeted for elimina­
tion from the United States, but 
an increase in the number of 
cases in HIV-infected persons, 
particularly IV drug users, has 
confounded that goal, and now 
the target date for elimination 
has been moved to the year 
2010. Control and elimination 
of tuberculosis will depend 
upon the development and use 
of better diagnostic techniques 
and better therapeutic regi­
mens. The Center for Infectious 
Diseases is investigating a 
number of new techniques for 
the rapid detection, isolation, 
and identification of Myco­
bacterium tuberculosis strains 
and other pathogenic and op­
portunistic mycobacterial spe­
cies. These efforts involve iden­
tification of unique mycolic 
acids in mycobacteria by high 
performance liquid chromatog­
raphy, determination of myco­
bacterial species specific fatty 
acid profiles by gas-liquid 
chromatography, identification 
of specific mycobacterial pro­
teins by immunologic meth­
ods, and assay of DNA 
sequences unique to each my­
cobacterial species and strain. 
The latter will lead to systems 
for the detection and identifica­
tion of small numbers of myco­
bacteria via amplification of 
their DNA (using the polym­
erase chain reaction— PCR). 
These approaches will lead to 
earlier detection of infected 
persons— a crucial element in 
interrupting the chain of trans­
mission and eliminating the 
burden of this devastating 
disease.
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H EPA TITIS B: Hepatitis B virus infection 
remains one of the major public health problems 
in the United States. Approximately 300,000 
infections occur annually, causing 75,000 cases 
of acute hepatitis, 25,000 cases of chronic hepati­
tis, and 5,000-6,000 deaths from these diseases, 
cirrhosis, and liver cancer. The cost of this dis­
ease exceeds $720 million per year. Disease 
occurs primarily in young adults at risk because 
of lifestyle or occupation, but about 30 percent of 
cases occur in persons not belonging to any 
defined risk group. An effective hepatitis B 
vaccine became available in 1982, and immuni­
zation was recommended for groups at high risk 
of infection. Despite immunization of more than 
1.4 million persons, disease incidence has 
increased by 50 percent in recent years. The 
primary reason for this failure of current 
immunization programs has been the difficulty 
in delivering vaccine to adult high-risk groups. 
The high cost of vaccine has also been a major 
constraint. This failure has necessitated the de­
velopment of a new vaccination strategy. There 
are several parts to this new strategy, each to be 
implemented in sequence: first, universal screen­
ing of pregnant women and immunization of
infants born to hepatitis B virus-carrier mothers; 
at the same time, continuation of immunization 
of individuals in high-risk groups (e.g., health­
care workers, refugees from endemic-disease 
areas, persons using STD clinics, drug users 
accessed through rehabilitation programs or 
prisons); at the same time, continuation of im­
munization programs in areas of high ende- 
micity of infection; later, universal immuniza­
tion of infants; and finally, universal immuniza­
tion of adolescents. This is an ambitious long­
term program, worthy of the mission of the Cen­
ters for Disease Control. This approach could 
eliminate hepatitis B transmission as a signifi­
cant health problem by the year 2015. This strat­
egy would lead to prevention of disease by pro­
viding immunity from infection prior to initia­
tion of risk-taking behavior in adolescence and 
young adulthood and would eliminate the 30 
percent of infections in persons without known 
risk factors. This strategy will be most effec­
tively accomplished by utilizing the established 
health-care system, at the point of prenatal care, 
birth in the hospital, routine infant immuniza­
tion, and various school or special health 
encounters.
hepatitis B virus infection remains one of the major public health problems in the United 
States; 300,000 infections occur annually, causing 75,000 cases of acute hepatitis, 25,000 cases
of chronic hepatitis, and 5,000-6,000 deaths
in the Center for Infectious Diseases, work on rotavirus 
diarrhea includes laboratory analysis of viral genetic 
and antigenic diversity and assessment of candidate 
-the goal is a vaccine for all childrenvacctnes-
RO TA V IRU S D IA RR H EA : Rotavirus is the most 
common cause of serious diarrhea in American children. 
Every child is infected in its first three to four years of 
life, leading to an estimated three million cases of diar­
rhea, 500,000 doctor visits, 70,000 hospitalizations for
300,000 inpatient days, 75-125 deaths, and costs of hospi­
tal care of $200-400 million per year. Worldwide, nearly 
one million children die each year of rotavirus diarrhea. 
Vaccines currently being developed are likely to provide 
a means to prevent this important cause of childhood 
mortality and morbidity. In the Center for Infectious Dis­
eases, field studies are addressing basic questions about 
safety and efficacy of different candidate vaccines. Infor­
mation from these studies, plus 
laboratory-based studies on the 
genetic, antigenic, and immun­
ologic characteristics of rota­
viruses, should pave the way for 
identifying a safe and effective 
vaccine that can be incorporated 
into routine childhood immuni­
zations. Through a national surveil­
lance and laboratory program, pat­
terns of virus transmission and 
virus variation are being deter­
mined. This information, coupled 
with mortality and hospitalization 
data, provides estimates on the dis­
ease burden and will allow moni­
toring of rotavirus vaccination pro­
grams in the future.
G IA RD IA SIS: Enteric parasitic 
diseases are being recognized with 
increasing frequency in the United 
States; an estimated four million people 
are affected by Giardia lamblia every 
year. Costs for diagnostic tests, therapy, 
hospitalization, and absence from work 
are estimated to be more than $120 
million per year. The number of water­
borne outbreaks of giardiasis has 
increased significantly in recent years; 
the organism has been implicated in 37 
percent of 378 waterborne outbreaks of 
diarrhea investigated since 1976. W a­
terborne transmission most often 
occurs because of ineffective filtration 
or inadequate pretreatment of surface 
water (lakes, rivers, and streams) by 
municipal utilities. Giardia is also a 
well-recognized cause of diarrhea out­
breaks in day-care centers and is also an 
endemic pathogen in day-care centers. 
In outbreak investigations, 10-50 per­
cent of diaper-aged children have been 
found to be infected, and Giardia has 
been identified in 10-15 percent of 
diaper-aged children attending day­
care centers. Spread of the organism in 
day-care centers is favored by close 
interpersonal contact, frequent hand-to- 
mouth and object-to-mouth behavior, 
and fecal incontinence. While 
secondary spread of Giardia is espe­
cially frequent among toddlers, 
transmission to children of other ages, 
child-care workers, and household
efforts to reduce transmission of Giardia include 
identification of risk factors, development and assessment 
of control strategies, and application of better diagnostic 
techniques
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contacts is also common. About 20-25 percent of 
day-care center staff and family contacts of 
infected children become infected. The goal of 
the program of the Center for Infectious Dis­
eases is to reduce transmission of Giardia 
through identification of risk factors, develop­
ment and implementation of control strategies 
that address these risk factors, evaluation of the 
efficacy of control strategies, and development 
of more rapid and sensitive diagnostic 
techniques.
M A LA RIA : Malaria is one of the most prevalent 
and important infectious diseases in the world; 
it is estimated that 200-400 million persons are 
infected or reinfected annually. The highest 
mortality is in young children and pregnant 
women. In Africa, south of the Sahara, the most 
virulent malarial species, Plasmodium falciparum, 
is the cause of 5 to 12 percent of 
all deaths. In the United States, 
malaria is transmitted occasion­
ally in California and in south­
eastern states, but more impor­
tantly, every year several 
million people are exposed in 
the course of international 
travel, and approximately 1,000 
cases are reported in returning 
travelers. The spread of Plas­
modium falciparum  strains 
resistant to malaria drugs, 
especially chloroquine, compli­
cates prevention recommenda­
tions for travelers. The program 
of the Center for Infectious 
Diseases is focused on 
increasing the proportion of 
travelers using effective pre­
vention methods; improving 
surveillance of infected 
travelers returning to the 
United States; developing 
strategies for the control of 
malaria-associated mortality in 
Africa, via collaboration with 
concerned national 
governments and the World 
Health Organization; and 
defining the clinical and 
immunologic bases for natu­
rally acquired immunity to ma­
laria. These epidemiologic and 
laboratory approaches are
based on the premise that improved under­
standing of the malaria protozoan parasite, the 
infection it causes, and its mosquito vectors 
must be at the heart of efforts to limit its health 
impact. In the tropics, historically, malaria 
control has relied on insecticides. This strategy, 
while highly effective in some areas, is failing in 
many other areas because of the high cost and 
potential toxicity of insecticides. In this situation, 
more effort is being devoted to community- 
based programs to assure prompt and effective 
therapy for acutely infected children; these pro­
grams operate in the context of primary health 
care and are proving to be effective in reducing 
mortality rates. Malaria vaccines may constitute 
an important control method in the future, but 
for the present, expansion of therapy programs 
is the most realistic and affordable approach 
available.
malaria is one of the most important infectious diseases in 
the world— it is estimated that 200-400 million persons are 
infected annually—in sub-Saharan Africa malaria is the 
cause of 5-12 percent of all deaths—highest mortality is in 
young children and pregnant women
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D EN G UE: Dengue is one of the most rapidly 
expanding diseases of the tropics, with mil­
lions of cases occurring each year. Puerto 
Rico had five epidemics in the first 75 years 
of this century but has had six epidemics in 
the past 11 years, at an estimated cost of over 
$150 million. Dengue transmission has oc­
curred twice in the continental United States 
in the past few years after an absence of 
thirty-five years. At the same time, there has 
been a record number of cases elsewhere in 
the Americas; Brazil, Bolivia, Paraguay, and 
Ecuador have experienced their first major 
dengue epidemics in over fifty years. The 
severe form of the disease, dengue hemor-
Aedes albopictus,
a newcomer to the 
Western Hemisphere 
and a proven 
vector of dengue 
virus
a poster used in Puerto Rico as part of a public education program run 
by the Center for Infectious Diseases and Commonwealth and local
health departments
rhagic fever, is a leading cause of hospitalization 
and death of children in southeast Asia; in 1987 
there were over 600,000 cases reported. Dengue 
hemorrhagic fever first occurred in the Amer­
icas in 1981, in association with a major epi­
demic in Cuba. Since then, eleven countries in 
the Western Hemisphere have reported cases of 
dengue hemorrhagic fever, suggesting that this 
manifestation of dengue infection is evolving in 
the Americas now as it did in southeast Asia in 
the 1960s. In the absence of effective continuous 
mosquito control, again because of the high cost 
and concern over potential toxicity of 
insecticides, early warning of the presence of 
virus is the key to predicting impending epi­
demics. If epidemics can be predicted, they can 
be prevented by focused mosquito control. The 
Center for Infectious Diseases coordinates an 
international surveillance system for the Ameri­
cas in cooperation with the Pan American 
Health Organization and national health minis­
tries; this includes laboratory-based reference 
diagnostics and field-based serologic and mos­
quito vector surveillance in dengue-endemic 
countries.
PO LIO M YELITIS:
Paralytic poliomyelitis 
remains a serious public 
health problem in the de­
veloping countries of 
Africa and Asia— it still 
strikes as many as 400,000 
children per year. In 
some endemic-disease 
areas, attack rates exceed 
250 cases per 100,000 
infants and children per 
year. In 1985, the Pan 
American Health Organi­
zation proposed the 
elimination of poliomye­
litis from the Americas by 
the year 1990. To mobi­
lize the substantial labo­
ratory support required 
for this program, the 
Center for Infectious Dis­
eases has led the devel­
opment of a network of 
collaborating laboratories 
throughout the Americas, 
pioneered in developing 
improved methods for 
identifying wild polio- 
viruses, transferred these methods within the 
network, and provided training and direct labo­
ratory support to network laboratories. This 
effort, and the national polio vaccination pro­
grams carried out in all countries of the Ameri­
cas, has been a great success. Now, the World 
Health Organization proposes total eradication 
of polioviruses from the world by the year 2000. 
This will require even more precise, rapid, and 
sensitive methods 
for the identifica­
tion of wild polio­
viruses in much 
more difficult 
circumstances.
Virologic data will 
have to be pro­
vided to indicate 
problem areas in 
national immuni­
zation programs 
so that vaccination 
resources can be 
directed most 
effectively.
poliovirus type 1 , 
electron micrograph, 
magnification x!80,000
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papillomaviruses, which are associated with cervical and 
esophageal cancer, cannot be grown in the laboratory—  
recombinant-DNA technologies are used in the Center for 
Infectious Diseases for detecting and typing these viruses in 
clinical specimens
PA PILLO M A TO SIS AND CAN CERS OF TH E CERVIX  
AND ESO PH A G U S: The association between human papillo­
mavirus infection and cancers is now firmly established. More 
than 85 percent of intraepithelial and invasive cervical cancers 
contain papillomavirus DNA. The same kind of association 
between papillomaviruses and esophageal cancer is suggested 
by the identification of viral DNA in tissues of 30-50 percent 
of cases. These findings do not explain how papillomaviruses 
cause these cancers, but they do focus attention on specific di­
agnostic approaches for early detection of infection, so as to 
guide clinical management and the prevention of trans­
mission— and they point to a longer-term goal of prevention of 
these cancers by papillomavirus vaccination. This is a worthy 
enterprise: despite reductions in cervical cancer rates in the 
United States in recent years (because of cytologic screening 
programs and earlier surgical intervention), there are still
7,000 deaths per year, and there is a threat that this will 
increase because of dramatic increases in the incidence of 
genital papillomatosis. Papillomaviruses cannot be grown in 
cell cultures, so recombinant-DNA and synthetic peptide tech­
nologies are used in the Center for Infectious Diseases for di­
agnosis and further research: viral DNA amplification from 
small tissue biopsies (via the polymerase chain reaction— PCR) 
allows detection of the presence of virus and even allows 
identification of the viral type— there are more than 55 human 
papillomaviruses. A few of these viruses that have been best 
studied have distinct associations with particular types of 
precancerous lesions, and these lesions differ in their proba­
bility of progressing to cancer. In the Center for Infectious Dis­
eases, efforts center on determining the risk associated with 
infection by the most recently discovered papillomavirus; this 
work involves analysis of unusual lesions and typical lesions 
in women in isolated populations with high incidences of
disease, such as Alaskan Natives. 
This work will further our under­
standing of the genetic diversity of 
these viruses and will lead to 
better diagnostic tests and better 
prevention strategies.
RA BIES: Rabies is still an 
important human disease in 
several areas of the world; for 
example, rabies kills some 50,000 
people per year in India. Animal 
rabies is important in many more 
areas, including the United States, 
where diagnostic laboratory re­
sponsibilities are growing as 
wildlife rabies increases. Foxes, 
skunks, raccoons, and insectivo­
rous bats maintain the virus in 
nature in various parts of the 
United States and transmit rabies 
to humans. Attempts to control 
wildlife rabies by poisoning or 
trapping animals have proved in­
effective, so wildlife vaccination 
programs are emerging as the 
method of choice. Vaccines suit­
able for use in wildlife species are 
under development in the Center 
for Infectious Diseases: genes for 
the important antigens of rabies 
virus have been cloned and ge­
netically transferred by recom­
binant-DNA technology into a 
harmless poxvirus (either vaccinia 
virus, which is the licensed small­
pox vaccine virus, or raccoonpox 
virus, a nonpathogenic virus 
found in nature). The poxvirus 
serves as the carrier or vector of 
the rabies virus genes, but the 
vectored poxvirus cannot cause 
rabies. A similar approach in­
volves the use of canine hepatitis 
virus as a vector; this virus is also 
found naturally in wild animals. 
When the vectored virus is inocu­
lated, it grows to a limited extent, 
and while doing so it expresses 
the rabies antigens. These antigens 
evoke a protective immune 
response, so that if later the vac­
cine recipient is exposed to rabies 
virus, there is no infection or
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Distribution of 5 antigenic variants of rabies virus 
and the predominant wildlife species affected
studies in the Center for Infectious Diseases, using monoclonal 
antibodies, have shown that different rabies virus strains are 
separately transmitted among different wild animal species—  
each must be dealt with specifically
disease. These vaccines have been tested in experimental ani­
mals in the laboratory and are now ready for comprehensive 
animal field trials. To protect wild animals, these vaccines will 
be delivered in baits that are attractive to particular species, 
such as raccoons and foxes. These vaccines offer for the first 
time an opportunity to control wildlife-borne rabies, and at the 
same time they offer an opportunity to protect dwindling 
wildlife resources.
LYM E D ISEA SE: Since the first cases of Lyme disease were 
described in 1976, the disease has extended far beyond the 
originally recognized foci in the Northeast to involve most 
states. It is estimated that there are more than 10,000 cases oc­
curring annually in the United States, more than the total of all 
other vector-borne diseases combined. Increased recognition 
and reporting are 
only partially respon­
sible for this increase: 
convincing arguments 
have been advanced 
that the number and 
range of the principal 
tick vector, Ixodes 
dammini, have 
increased because of 
the increase in the 
population of white­
tailed deer on which 
the tick feeds. Ex­
panded surveillance 
and research projects
are under way in the Center for 
Infectious Diseases; these include 
the evaluation of strategies to 
prevent exposure (using personal 
protective measures and ecologic 
modifications), field studies to 
define vectors in areas of the 
country outside the range of 
Ixodes dammini, and development 
and evaluation of new diagnostic 
tests.
V IR A L H EM O RRH A G IC  
FEV ERS: Some viruses must be 
worked with only in the Maxi­
mum Containment Laboratory 
(Biosafety Level 4): Marburg, 
Ebola, Lassa, Junin (the cause of 
Argentine hemorrhagic fever), 
Machupo (the cause of Bolivian 
hemorrhagic fever), Congo- 
Crimean hemorrhagic fever, and 
tick-borne encephalitis complex 
viruses. All of these viruses cause 
either severe hemorrhagic fever 
or severe encephalitis. There are 
no effective vaccines to protect 
laboratory workers against these 
viruses, so the integrity of the 
physical biocontainment facility 
and the reliability of staff opera­
tions are crucial for carrying out 
necessary diagnostic responsibili­
ties and related applied research 
activities safely. All of these 
viruses cause important epidemic 
or sporadic diseases in the areas 
of the world where they occur; for 
example, it is estimated that there 
are more than 300,000 cases per 
year of Lassa fever in West Africa. 
The program of the Center for 
Infectious Diseases is focused on 
preventing the introduction of 
these viruses into the United 
States and on leading efforts to 
minimize the impact of these 
viruses in countries where they 
occur. These prevention and 
control programs are operated in 
cooperation with the World 
Health Organization and health 
ministries in the countries in­
volved.
s
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Ebola virus, electron micrograph, magnification x60,000 —  
in 1989-1990 a related virus ivas introduced into the United 
States in imported monkeys, prompting comprehensive 
quarantine actions
N EW  AN D  EM ERG IN G  D ISEA SES, N EW  AND EM ER G ­
ING IN FECTIO U S A G EN TS, AND U N KN O W N S  
(D IA G N O STIC SPECIM EN S TH O U G H T TO CO N TAIN  
N EW  PA TH O G EN S): New or previously unrecognized in­
fectious agents are constantly being identified— the idea that 
"there is nothing new under the sun" is certainly not the case 
when it comes to infectious agents and infectious diseases. 
There is no way to predict when or where the next important 
new pathogenic microorganism will emerge. Likewise, there 
is no way to predict the significance of such a microorganism 
as it emerges— it might emerge as the cause of a geographi­
cally limited problem, or as the cause of new outbreaks, or as 
the cause of a new epidemic. No one would have predicted 
the emergence of M arburg and Ebola viruses from their still 
unknown econiches in Africa in 1967 and 1976, and no one 
would have predicted the introduction of Ebola virus into the 
United States via wild-caught imported monkeys in 1989; no 
one would have predicted the emergence of the Legion­
naires' disease bacterium , Legionella pneumophila, before 
the investigation of the epidemic of unusual pneumonia in 
Pennsylvania in 1976; and certainly no one would have 
predicted the epidemic emergence of hum an im m uno­
deficiency virus, HIV, as the cause of AIDS before the dis­
covery of the virus in the early 1980s. When a new infectious 
agent is suspected, it must be isolated, identified, character­
ized, and developed into systems for diagnosis and field in­
vestigation. When a new infectious disease is suspected, it 
must be characterized (by the work of clinicians and patholo­
gists and other clinical support specialists), and assessed in 
regard to its impact on populations at risk (by the work of
medical epidemiologists and other 
support specialists). These activities 
must be highly integrated to 
develop a comprehensive view of 
the potential or immediate problem 
at hand; this kind of 
integrated, investigative, problem­
solving approach is the stock-in- 
trade of the Center for Infectious 
Diseases. This approach is the key 
to guiding prevention and control 
measures as these become neces­
sary. This approach for assessing 
risk and guiding intervention 
involves diverse elements; for ex­
ample, in some cases, complex 
field studies of the incidence of 
infection in the general population 
or in selected subpopulations are 
necessary to determine risk factors 
for infection, mode of transmission, 
targets for intervention, etc., while 
in other cases, complex studies of 
pathogenetic mechanisms of the 
infection or the molecular biology 
of the agent hold the key to further 
action. The following examples 
illustrate this complex and diverse 
enterprise:
H um an herpesvirus 6 was discov­
ered just a few years ago; it was 
isolated first from an AIDS patient 
by a method that is used to isolate 
HIV, the causative agent of AIDS. 
Since then, the virus has been the 
subject of much investigation in the 
Center for Infectious Diseases. At 
first the virus was a curiosity, the 
subject of much speculation as to 
its pathogenic potential, but in 
short order it was isolated from 
children with roseola infantum 
(one of the common rash diseases 
of children), and then it was 
isolated from B-cell lymphoma 
patients and organ-transplant 
patients. The virus was also iso­
lated from healthy adults, and 
seroepidemiologic studies indi­
cated that infection is common in 
the general population. So, in the 
course of a few years a complex, 
but still incomplete, natural history
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and public health picture has emerged from an 
initial misbelief that all human herpesviruses had 
already been discovered.
Chlamydia pneumoniae was discovered in 1986 as 
an important yet unrecognized cause of adult 
pneumonia. Chlamydial organisms had previ­
ously been recognized as important causes of 
genital disease, and in developing countries, 
blindness, but never respiratory disease. Now, in 
the Center for Infectious Diseases, laboratory diag­
nostic systems are in advanced stages of develop­
ment, and further natural history, transmission, 
and epidemiologic studies are under way to assess 
this new organism's true public health impact.
Helicobacter pylori was discovered in 1982 in 
association with gastritis and peptic ulcer disease. 
The bacterium has been found in the gastric 
mucosa of 75-90 percent of persons with chronic 
gastritis and 50-70 percent of persons with peptic 
ulcer disease, diseases that are often prolonged 
and painful, and require expensive medical and 
surgical therapy. The organism was also found in 
20-40 percent of normal individuals. An 
unanswered question is whether the organism is 
the actual cause of gastritis or peptic ulcer disease 
or is just an incidental or opportunistic participant. 
If the organism proves to be a specific cause of 
these diseases, then simple, inexpensive treatment 
regimens (antimicrobial drug therapy) can be de­
veloped. Investigations to answer these 
outstanding questions are under way in the 
Center for Infectious Diseases.
Hum an parvovirus B19 was discovered a few 
years ago in England. Since then it has been 
shown to be the primary cause of erythema 
infectiosum (also called fifth disease, another of 
the common rash diseases of children) and aplas­
tic crisis (an important hemolytic anemia disease, 
especially serious in association with sickle cell 
disease). The virus has also been found in associa­
tion with arthritis, chronic anemia, and fetal death. 
Exposure by children with fifth disease of preg­
nant school teachers, day-care center workers, 
health-care workers, and other women has be­
come an important public health concern. Defin­
ing the risk to the fetus after different types of 
maternal exposure is essential for the develop­
ment of national recommendations; initial recom­
mendations have been made and investigations 
necessary to extend these recommendations are 
under way in the Center for Infectious Diseases.
Legionella pneumophila, the bacterium that 
causes Legionnaires' disease, has been found 
to grow intracellularly within free-living 
protozoa in some water supplies— this 
protects the bacterium from chlorination
M O D ERN  D IA G N O STICS: Traditionally, 
diagnosis of infectious agents has depended 
on microscopic examination of clinical speci­
mens or growth of the causative microorgan­
ism on an artificial medium or in cultured 
cells or in laboratory animals. While such 
methods may still be most appropriate in 
some cases, in too many other cases diagnosis 
has failed because of insensitivity of the 
method, intractable characteristics of the 
organism, or inactivation of the sample in 
transport. Two major research developments 
have occurred in recent years that open new 
prospects for diagnosis, namely the devel­
opment of monoclonal antibodies and the 
development of recombinant-DNA (genetic 
engineering) technologies. Both offer the 
prospect for major improvements in the speci­
ficity and consistency of diagnostic reagents. 
Coupled with advances in the electronics of 
instrumentation, breakthroughs are constantly 
occurring; the Centers for Disease Control 
often plays a role as a leader or partner in 
such developments. Techniques being applied 
across the wide spectrum of infectious dis­
eases include: (a) development of m onoclonal 
antibodies specific for the various antigens 
that are common to groups of microorganisms 
(for screening tests) or limited to specific 
strains of microorganisms (for identification 
tests); (b) development of im m unologic test
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hnman herpesvirus 6, electron micrograph of an infected cell—  
in 1986 the virus was isolated first from an AIDS patient, next 
from children with roseola infantum (one of the common rash 
diseases of children), and then from B-cell lymphoma patients 
and organ-transplant patients
form ats suitable for automated instruments (for large scale se- 
roepidemiologic studies and intervention programs); (c) devel­
opment of synthetic peptides and genetically engineered proteins 
suitable as antigens in diagnostic tests; (d) development of syn­
thetic and genetically engineered m icrobial nucleic acids for use 
as probes in assays to detect infectious agents in tissues and other 
diagnostic specimens; and (e) development of m icrobial gene 
am plification technologies to detect exceptionally low levels of 
DNA or RNA of infectious agents (e.g., polymerase chain reac­
tion— PCR, and Q-beta replicase reaction— QBR technologies). For 
example, gene amplification technology is being used for the early 
diagnosis of Rocky Mountain spotted fever. This technology will 
permit earlier use of antimicrobial drug therapy. In a similar way, 
the polymerase chain reaction and monoclonal antibody-based 
dot-blot immunoassays are being used to identify Listeria monocy­
togenes in contaminated food products. These methods take 18 
hours rather than the 3-4  days of traditional methods, thereby ac­
celerating appropriate public health actions to remove contami­
nated food products from markets. As another example, a Western 
blot assay has been developed for neurocysticercosis, a central 
nervous system disease caused by a tapeworm. This disease is in­
creasing in the United States, especially in new immigrants from 
South America. The disease is confusing to physicians, who must 
differentiate it from brain tumors by CAT scan or other imaging 
techniques. The innovative laboratory assay developed in the 
Center for Infectious Diseases obviates unnecessary surgical proce­
dures because the tapeworm may be eliminated with 
medication.
M ODERN  VACCINE 
DEVELOPM EN T AND 
APPLICATION: Whoever 
coined the old saying, "an 
ounce of prevention is worth a 
pound of cure," may have had 
vaccines against infectious 
diseases in mind. Treatment 
of infected people is not al­
ways successful and can be 
difficult, expensive, and very 
demanding of the time of 
medical personnel. Prevention 
of disease by use of vaccines, 
on the other hand, is usually 
simple, safe, inexpensive, and 
long-lasting in effect. In some 
cases, vaccine use even offers 
the possibility for disease 
eradication, as has been the 
case with smallpox. Most 
present vaccines are com­
posed either of inactivated or 
living-attenuated microorgan­
isms; these vaccines have 
many positive attributes, but 
there are often shortcomings 
as well. Advances in biotech­
nology are providing unique 
opportunities for the develop­
ment of entirely new types of 
vaccines. In the Center for In­
fectious Diseases, research 
and development activities are 
being carried out in collabora­
tion with other agencies and 
institutions: important path­
ogenic microorganisms are 
being "taken apart," and their 
proteins (antigens) are ana­
lyzed to determine which are 
the best stimulators of protec­
tive immunity; genes coding 
for these antigens are then 
cloned (selectively amplified) 
using recombinant-DNA tech­
nology, and the genes are 
expressed to produce large 
amounts of antigens that can 
be formulated into vaccines. 
One such program in the 
Center for Infectious Diseases 
concerns malaria vaccine 
development.
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prevention of disease by use of vaccines is 
usually simple, safe, inexpensive, and long- 
lasting in effect
Malaria parasites cannot be grown in culture in the 
laboratory, so traditional methods of developing vac­
cines have not been feasible. However, in the past 
few years in three institutions around the world, the 
genes for the important proteins of malaria parasites 
have been cloned, their DNA sequences determined, 
and from this information the amino acid sequences 
of their proteins have been predicted. These amino 
acid sequences have been used to chemically syn­
thesize large amounts of proteins (peptides), which 
have been formulated into vaccines. In the Center for 
Infectious Diseases, these candidate vaccines are 
being injected into monkeys, which are then chal­
lenged with malaria parasites to evaluate their 
immunogenicity. Only by the use of such animal 
models can vaccines be judged ready for human 
trials— in this case, human trials are several years 
away, but there is a sense of hope that a new means 
of controlling malaria may be developed for use 
throughout tropical areas of the world. In the Center 
for Infectious Diseases, laboratory vaccine studies go 
hand in hand with epidemiologic studies; for ex­
ample, studies of the incidence of diseases point out 
important target populations for new vaccine usage. 
Epidemiologic studies also allow evaluation of the ef­
ficacy, frequency of adverse reactions, and duration 
of immunity of new vaccines. For example, Haemo­
philus influenzae type b vaccine is one subject of com­
bined epidemiologic and laboratory studies. This 
organism is the cause of serious disease, including 
meningitis, particularly in young children. Ongoing 
projects are evaluating the immune response in 
vaccinated children. These studies form an impor­
tant part of the overall efforts in the United States to 
make available to all children effective vaccines 
against all important infectious diseases.
A N TIM IC R O BIA L D RU G  RESISTA N CE:
Use of antimicrobial drugs in human and 
veterinary medicine and in animal feeds has 
resulted in the emergence of resistant 
bacterial pathogens. More recently, resis­
tance has also emerged in fungal, parasitic, 
and viral agents, including HIV. In addi­
tion, medical advances in organ trans­
plantation and the treatment of renal failure 
and cancer have introduced special prob­
lems in antibiotic usage. Antibiotic toxicity 
is an important cause of morbidity and may 
have significant economic and legal impli­
cations. Emergence of resistance provides 
challenges to improve surveillance of an­
timicrobial drug usage and resistance, 
apply modern laboratory techniques to de­
termine mechanisms of resistance, and 
develop innovative strategies to ensure 
optimal antimicrobial drug usage to maxi­
mize clinical benefit and minimize emer­
gence of resistant organisms in the future.
in the Center for Infectious Diseases 
important pathogenic microorganisms are 
being "taken apart" and their proteins 
assessed as stimulators of protective 
immunity— recombinant-DNA technology 
allows these proteins to be made in large 
amounts and formulated into candidate 
vaccines
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W O RLD H EALTH  O RG AN IZATIO N  CO LLABO RATING  CENTERS  
IN  THE CENTER FO R IN FECTIO U S D ISEASES
WHO Collaborating Center for Reference and Research on Acquired Immunodeficiency Syndrome (AIDS) 
WHO Collaborating Center for AIDS Research (Projet SID A, Zaire)
WHO Collaborating Center for Reference and Research on Arboviruses
WHO Collaborating Center for Reference and Research on Dengue (pending)
WHO Collaborating Center for Reference and Research on Influenza
WHO Collaborating Center for Reference and Research on Respiratory Viruses Other Than Influenza
WHO Collaborating Center for Reference and Research on Viral Hepatitis
WHO Collaborating Center for Reference and Research on Rabies
WHO Collaborating Center for Reference and Research on Smallpox and Other Poxviruses
WHO Collaborating Center for Reference and Research on Enteroviruses
WHO Collaborating Center for Reference and Research on Viral Special Pathogens
WHO Collaborating Center for Reference and Research on Syphilis
WHO Collaborating Center for Reference and Research on Escherichia
WHO Collaborating Center for Reference and Research on Klebsiella
WHO Collaborating Center for Reference and Research on Salmonella
WHO Collaborating Center for Reference and Research on Shigella
WHO Collaborating Center for Reference and Research on Plague
WHO Collaborating Center for Staphylococcus Phage Typing
WHO Collaborating Center for Enteric Phage Typing
WHO Collaborating Center for Reference and Research on Rickettsia
FAO/WHO Collaborating Center for the Epidemiology of Leptospirosis
WHO Collaborating Center for Mycotic Diseases
WHO Collaborating Center for Host and Parasite Studies on Malaria
WHO Collaborating Center for Research, Training, and Control of Dracunculiasis
WHO Collaborating Center for Research on Basic Principles of Insecticide Formulations
WHO Collaborating Center for Human Immunoglobulins
WHO Collaborating Center for Reference and Research on Antibiotics and Antibiotic Substances 
WHO Collaborating Center for Reference and Research Services for Standardization of Diagnostics
OTHER WORLD HEALTH ORGANIZATION COLLABORATING CENTERS 
AT THE CENTERS FOR DISEASE CONTROL THAT RELATE TO THE PROGRAMS  
OF THE CENTER FOR INFECTIOUS DISEASES:
WHO Collaborating Center for Applied Biosafety Programs and Training  
WHO Collaborating Center for Classification of Diseases in North America
WHO Collaborating Center for Development of Integrated Primary Care Programs for Community Practice
WHO Collaborating Center for Research Training in Human Reproduction
WHO Collaborating Center for Immunization Activities
WHO Collaborating Center for Epidemiology Training
WHO Collaborating Center for Occupational Health
WHO Collaborating Center for Perinatal Care and Health Service Research in Maternal and Child Health 
WHO Collaborating Center for Disaster Preparedness and Response
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THE D IVISIO N S A N D  PRO G RAM S OF  
THE CENTER FO R IN FECTIO U S D ISEASES
D IV ISIO N  OF BA CTERIA L AND M YCO TIC  
D ISEA SES: The Division of Bacterial and 
Mycotic Diseases operates at the forefront of the 
microbiologic and infectious disease sciences, 
fulfilling its mission of disease surveillance, epi­
demiologic and laboratory investigation, and 
reference services. The Division's activities 
encompass the many bacterial and mycotic dis­
eases of public health importance in the United 
States and internationally. The Division’s activ­
ities are advancing in scope and sophistication 
in keeping with ongoing changes in disease 
incidence and trends and in antimicrobial drug 
resistance patterns. The Division is in the midst 
of a technologic revolution, bringing more and 
more new and powerful approaches to bear on 
microbial and mycotic diagnostic and reference 
identification responsibilities. The Division is 
also in the midst of a revolution in epidemiol­
ogic and statistical approaches being brought to 
bear on important bacterial and mycotic 
diseases.
Even in this age of antimicrobial and antimy- 
cotic drugs, bacterial and mycotic agents con­
tinue to be the cause of many important enteric, 
respiratory, and central nervous system dis­
eases. The nature of most bacterial and fungal 
diseases is such that a rapid response is the key 
to controlling episodes and outbreaks— epide­
miologic investigation, special disease surveil­
lance, laboratory studies, and consultation with 
concerned State and local health agencies must 
usually be done without delay— the Division 
takes pride in its reputation for rapid expert 
response.
The Division's laboratories support its 
epidemiologic activities by defining involved 
etiologic agents, developing diagnostic tests, 
studying how bacterial and mycotic agents 
cause illness, and serving as reference centers 
for State and other laboratories. The Division 
houses World Health Organization collaborat­
ing centers for several types of bacteria,
including Shigella, Salmonella, Escherichia, 
Leptospira, and Mycobacterium , and also for 
mycotic agents of disease.
Societal and technologic changes are influencing 
the occurrence of bacterial and mycotic diseases. 
With advances in food processing and transport 
methods, opportunities for the development and 
spread of foodborne bacterial agents are increas­
ing. New or previously little-known foodborne 
pathogens, such as Escherichia coli 0157:H7 and 
Listeria monocytogenes, call for revised surveil­
lance approaches and prevention strategies.
With the widespread use of antibiotics, new an­
timicrobial drug resistance patterns are becom­
ing of great concern— this is especially the case 
with Salmonella species, Shigella species, Strepto­
coccus pneumoniae, and Staphylococcus aureus. 
With the increase in numbers of immunocom­
promised patients (due to cancers, HIV infec­
tion, and the use of drugs in association with 
organ transplant surgery), there are new prob­
lems being caused by opportunistic mycotic and 
bacterial pathogens. Finally, societal changes 
have resulted in new infectious disease prob­
lems in new settings, such as in out-of-home 
child-care centers, hospitals, and extended-care 
facilities; increasing efforts are being made to 
deliver prevention and control strategies in 
such specialized settings. These and most other 
efforts require increasing cooperation between 
all concerned parties. In this regard, the Divi­
sion is working hard to extend its collaborative 
efforts nationally and internationally with gov­
ernmental, educational, and private agencies 
concerned with bacterial and mycotic disease 
prevention and control.
D IVISIO N  OF H IV /A ID S: The Division of 
H IV/A ID S is actively involved in efforts to 
characterize human immunodeficiency virus 
(HIV) infection and to define the scope and 
magnitude of the acquired immunodeficiency 
syndrome (AIDS) epidemic in the United States 
and around the world. These efforts center
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around HIV/  AIDS surveillance activities and 
national and international epidemiologic and 
laboratory investigations.
In collaboration with State, local, and territorial 
health departments, the Division conducts and 
manages national surveillance of AIDS cases 
and coordinates studies of the incidence and 
prevalence of HIV infection in the United States. 
Begun in 1981, AIDS case surveillance has 
provided the scientific basis for HIV / AIDS pre­
vention and control recommendations and con­
tinues to yield essential information about the 
epidemiologic features of this disease. As 
surveillance methods are expanded to include 
the full spectrum of HIV disease, these data will 
continue to be an essential element in the overall 
assessment of the impact of the HIV epidemic. 
Complementing AIDS case surveillance, HIV 
surveillance is conducted through the "fam ily" 
of seroprevalence surveys, a national network of 
surveys and studies in selected subgroups 
across geographically diverse areas of the 
United States. The addition of these data to the 
body of knowledge about H IV/  AIDS broadens 
our understanding of the dynamics of the 
epidemic substantially.
Taken together, AIDS surveillance data and HIV 
seroprevalence data provide information for 
monitoring the H IV /A ID S epidemic. These 
data allow the determination of infection trends 
in risk groups and trends in HIV transmission. 
In turn, these data allow AIDS case projections 
into the future, thereby supporting projections 
of national resource needs for future prevention 
and treatment programs.
Epidemiologic studies conducted in 
collaboration with health departments, medical 
centers, blood banks, and other national organi­
zations and through collaborative agreements 
internationally have identified HIV risk factors 
and transmission patterns and clarified the 
natural history of HIV infection in adults and 
children. Ongoing studies will refine what is 
already known and provide further insight into 
areas such as biologic factors influencing HIV 
transmission, viral infectivity and virulence, 
and issues related to drug use. Laboratory inves­
tigations have resulted in the development of 
procedures for HIV isolation, characterization, 
and serodiagnosis. The Division's laboratories
serve as a national reference center for HIV-1 
and HIV-2 serologic testing. Important ad­
vances in our understanding of the nature of 
HIV infection have come through the the initial 
application of the polymerase chain reaction 
technique. HIV viral genome sequence analy­
ses, improved Western blot methodology, and 
novel immunoassays have also contributed to 
our understanding of the natural history of HIV 
and to the pathogenesis of the disease AIDS.
The Division also provides epidemiologic, 
surveillance, and technical advice and assis­
tance to State and local health departments, 
other governmental agencies, and medical 
institutions. The Division serves as a World 
Health Organization Collaborating Center for 
Reference and Research on H IV/ AIDS.
D IV ISIO N  OF IM M U N O LO G IC, O N CO ­
LO G IC, AND H EM A TO LO G IC D ISEA SES:
The Division of Immunologic, Oncologic, and 
Hematologic Diseases conducts integrated epi­
demiologic and laboratory investigations into 
the roles of infectious agents in cancer and 
diseases of the immune and hematologic sys­
tems, applying investigative and analytical 
epidemiologic methods and state-of-the-art mo­
lecular biologic techniques to important disease 
problems of today.
The Division works to clarify biologic processes 
involved in the development of certain dis­
eases, and works to find the etiologic agents of 
certain diseases which on the basis of epidemi­
ologic patterns and trends seem to be transmit­
ted from person to person. In each case, preven­
tive measures are sought. The Division is 
focusing its etiologic agent searching on 
Hodgkin's disease, leukemias, and lymphomas. 
Methods for early detection of tumors are being 
tested by epidemiologic field studies of certain 
leukemias and bladder cancers. The Division 
also conducts investigations to improve the 
sensitivity, specificity, accuracy, and efficiency 
of immunodiagnostic laboratory methods, and 
develops immunochemical methods and rea­
gents for detecting and identifying infectious 
agents of public health importance. The Division 
also provides reference diagnostic tests in hema­
tology, immunohematology, clinical chemistry, 
and hemoglobinopathies.
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D IV ISIO N  OF PA RA SITIC D ISEA SES: The
Division of Parasitic Diseases is concerned with 
the important protozoan and helminthic dis­
eases of the United States and developing coun­
tries of the tropics. The Division is staffed by a 
multidisciplinary group of medical epidemiolo­
gists, parasitologists, immunologists, molecular 
biologists, analytical chemists, and entomolo­
gists involved in surveillance, epidemiologic 
investigations, and field and laboratory 
research. The Division collaborates closely with 
a wide spectrum of local, national, and interna­
tional groups including State and local health 
departments, the Carter Presidential Center of 
Emory University, the World Health Organiza­
tion, the United States Agency for International 
Development, and the United States Peace 
Corps.
Parasitic diseases represent significant health 
problems in the United States. Major domestic 
programs of the Division deal with malaria and 
other parasitic diseases in U.S. travelers to other 
countries, infectious diseases in out-of-home 
child-care centers, opportunistic infections in 
AIDS patients, and waterborne diseases.
The Division also has extensive international 
activities aimed at the prevention and control of 
malaria, filariasis, schistosomiasis, dracunculia- 
sis (guinea worm disease), and intestinal para­
sites. The Division has field stations in Kenya 
and Guatemala involved in epidemiologic 
studies of these diseases.
The Division focuses its efforts in a variety of 
ways, including: 1) surveillance and epidemio­
logic investigation of parasitic diseases to define 
disease etiology, mode of transmission, and 
populations at risk and to develop effective 
methods for diagnosis, prevention, and control; 
2) research and training in the epidemiology 
and control of arthropod vectors and intermedi­
ate hosts of human parasites; 3) epidemic aid 
and epidemiologic consultation; 4) reference 
diagnostic services for parasitic diseases to State 
health departments; 5) laboratory studies of 
parasitic infections, emphasizing in vivo and in 
vitro systems; 6) research, development, and 
evaluation of immunizing agents and the role of 
protective immunity in parasitic disease pro­
cesses; and 7) scientific and technical assistance 
to various domestic and international groups.
D IVISIO N  OF SEXU A LLY TRA N SM ITTED  
D ISEASES LA BO RA T O R Y RESEA RC H : The
Division of Sexually Transmitted Diseases 
Laboratory Research applies modern microbiol­
ogic and immunologic methods to study the pa­
thogenesis, genetics, immunology, and labora­
tory identification of the bacterial and 
chlamydial agents of sexually transmitted 
diseases (STDs). The Division provides labora­
tory support for collaborative studies on the epi­
demiology and treatment of such STDs as 
gonorrhea, syphilis, chancroid, and chlamydial 
and mycoplasmal infections.
An important focus of the Division is to define 
the extent and nature of the increasing resis­
tance of Neisseria gonorrhoeae isolates to antimi­
crobial drugs. The Division is also studying 
changes in gonococcal organisms within com­
munities and is working to identify and charac­
terize gonococcal components that may be 
useful as a candidate vaccine. Another activity 
concerns the improvement of laboratory meth­
ods for the diagnosis of gonorrhea and for the 
determination of gonococcal antimicrobial drug 
susceptibility.
In view of the growing number of chlamydial 
infections in the United States today, the Divi­
sion is increasing its efforts to accurately esti­
mate chlamydia prevalence, to identify popula­
tions at risk, and to diagnose Chlamydia infec­
tions by rapid and sensitive laboratory methods.
The Division also investigates laboratory aspects 
of syphilis and other treponemal infections; con­
sultation and reference diagnostic services for 
syphilis are provided for State and local health 
departments. The Division serves as a WHO 
Collaborating Center for Reference and Research 
on Syphilis.
D IV ISIO N  OF V EC TO R -BO R N E IN FEC ­
TIO US D ISEA SES: The Division of Vector- 
Borne Infectious Diseases investigates national 
and international outbreaks of viral and bacte­
rial diseases transmitted to humans by arthro­
pods. The Division conducts laboratory and epi­
demiologic research to improve the diagnosis of 
and prevention strategies for yellow fever, 
dengue, dengue hemorrhagic fever, Japanese 
encephalitis, plague, tularemia, relapsing fever, 
Lyme disease, and other vector-borne diseases.
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The Division serves as a World Health 
Organization and Pan American Health Organi­
zation Collaborating Center for Reference and 
Research on Dengue and Dengue Hemorrhagic 
Fever. The Division manages an international 
training center in Puerto Rico for teaching 
dengue prevention and control methods to 
public health officers from throughout the West­
ern Hemisphere. Within the Division are two 
other World Health Organization Collaborating 
Centers for Reference and Research, one for 
arboviruses and the other for plague. The Divi­
sion maintains ties with public health agencies, 
universities, and medical research institutions 
throughout the world, with particular emphasis 
placed on vector control. The Division manages 
a national surveillance system and a national 
reference laboratory for Lyme disease. This, in 
turn, contributes importantly to collaborative 
studies with State and local health agencies to 
identify risk factors and to establish strategies 
for the prevention of Lyme disease.
D IV ISIO N  OF V IRA L AND RICKETTSIA L  
D ISEA SES: The Division of Viral and Rick­
ettsial Diseases carries out comprehensive pro­
grams to prevent morbidity and mortality 
caused by the many viral and rickettsial diseases 
of national and worldwide importance. The 
Division fully integrates modern laboratory and 
epidemiologic sciences for the accomplishment 
of its mission; disease surveillance and epidemi­
ologic field investigations are integrated with 
microbiologic and molecular biologic laboratory 
technologies and many special reference diag­
nostic services. The Division is conducting 
major programs for the prevention and control 
of hepatitis, influenza, viral respiratory diseases, 
viral diarrheal diseases, rickettsial diseases, 
zoonotic diseases, and diseases caused by exotic 
and dangerous viral and rickettsial pathogens. 
The Division's activities in these areas are 
leading to the application of new and novel 
prevention strategies throughout the United 
States and worldwide. Approaches include the 
refining of surveillance systems for assessing 
disease incidence and impact, developing inno­
vative diagnostic approaches to allow early di­
agnosis and identification of etiologic agents, 
and designing focused epidemiologic studies of 
disease trends, natural history, and transmission 
patterns. For example, preventive measures for 
influenza have been improved significantly as a
result of advances in surveillance techniques 
that permit earlier detection of antigenic vari­
ants and by the use of highly sensitive tests for 
the rapid diagnosis and analysis of influenza 
viruses. The application of this kind of inte­
grated disease prevention and control approach 
in turn leads to improved public health inter­
vention strategies. For example, current national 
efforts to reduce the incidence of hepatitis B 
through universal immunization of infants and 
adolescents are based on continuing epidemio­
logic studies of disease trends and vaccine 
efficacy. The same kind of integrated disease 
prevention and control approach is being used 
to address new and emerging infectious dis­
eases and to incriminate viruses as the cause of 
certain cancers and degenerative conditions.
For example, hepatitis B has been shown to 
cause primary hepatocellular carcinoma, the 
most common cancer in the world, and associa­
tions have also been demonstrated for human 
papillomavirus and cervical cancer, Epstein-Barr 
virus and nasopharyngeal cancer, and HTLV-I 
and adult T-cell lymphoma. Within the Divi­
sion, there are eight WHO Collaborating Centers 
for Reference and Research.
A RCTIC IN V ESTIG A TIO N S PRO G RA M : The
Arctic Investigations Program, located in An­
chorage, Alaska, conducts epidemiologic and 
laboratory investigations on infectious disease 
problems of Arctic and sub-Arctic populations, 
especially Alaskan Natives (Eskimos, Aleuts, In­
dians). Program emphasis is on applied epi­
demiology; the latest knowledge and technology 
is used to direct programs for the prevention 
and control of diseases in widely scattered, 
sparsely distributed populations. Activities 
include disease surveillance, investigation of 
disease etiology, analytic and descriptive epi­
demiologic studies, development of laboratory 
methods, evaluation of intervention strategies, 
dissemination of information, and training in 
research, epidemiology, and public health.
Major emphasis is on prevention and control of 
hepatitis B, Haemophilus influenzae type b infec­
tion, and streptococcal pneumonia. Hepatitis B 
studies include evaluating long-term sequelae 
(cancer, cirrhosis) of infection, and detecting 
early resectable liver cancers through alpha- 
fetoprotein screening of carriers. In Haemophilus 
influenzae studies, the focus is on
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immunogenicity studies of vaccines for infants 
under 6 months of age. In pneumococcal disease 
studies, increased surveillance, studies of dis­
ease incidence, characterization of isolates in­
cluding serotype and antibiotic resistance, de­
velopment of rapid diagnostic tests, and 
evaluation and better use of current pneumococ­
cal vaccines are in progress.
Botulism and Echinococcus multilocularis 
infections are two diseases with unique impact 
in the Arctic. Botulism occurs after consumption 
of certain native foods. Studies are under way to 
assess the pharmacodynamics of antitoxin and 
to develop rapid laboratory methods for identifi­
cation of toxin in food or body fluids. Echinococ­
cus multilocularis infection results in severe liver 
disease; transmission to humans occurs by ex­
posure to dogs or foxes. Control is focused on 
reducing primary infection and on screening the 
high-risk population with a newly developed 
blood test. Work is also ongoing on long-term 
sequelae of infectious diseases, particularly 
virus-associated cancers (such as cervical 
cancer, which is associated with papillomavirus 
infection). Much of this work is done via col­
laborative efforts involving the Indian Health 
Service, the State health department of Alaska, 
universities, and other agencies.
H O SPITA L IN FECTIO N S PRO G RA M : The
Hospital Infections Program conducts active 
surveillance and ongoing epidemiologic and 
laboratory investigations of existing as well as 
emerging nosocomial infection problems. These 
activities are designed to lower rates of and 
identify risk factors for hospital-acquired 
infections. The Program serves as a national 
focus for issuing recommendations and guide­
lines for prevention and control of hospital in­
fections, including occupational HIV infections, 
and for sterilization and disinfection techniques 
for health-care settings.
The Program's National Nosocomial Infections 
Surveillance (NNIS) system provides national 
nosocomial infection rates to acute-care facili­
ties, national health organizations, and the 
public. Since introduction of NNIS surveillance 
components in 1986, implementation has stead­
ily increased. Knowledge of nosocomial infec­
tion rates can serve as a stimulus for facilities to 
evaluate their infection control programs and
can provide a "benchmark" for national com­
parisons. Preliminary evidence has indicated 
that reporting these infection rates back to par­
ticipating hospitals can result in significant 
reductions in nosocomial infections.
New laboratory research techniques, such as 
polymerase chain reaction and ribotyping, 
which allow for rapid detection an d /or genetic 
characterization of nosocomial pathogens have 
recently been employed to study transmission of 
hospital infections. Molecular techniques are 
also being used to determine the mechanisms of 
bacterial resistance. The Program’s laboratories 
serve as World Health Organization Collaborat­
ing Centers for Staphylococcus Phage Typing, for 
Reference and Research on Klebsiella, and for 
Antibiotics and Antimicrobial Substances.
The Program collaborates with national and 
international agencies and infection control 
organizations to reduce the incidence of noso­
comial infections by evaluating current preven­
tion strategies, such as those protecting health­
care workers from acquiring bloodborne dis­
eases from patients, as to their effect on the 
incidence of nosocomial infections in patients. 
Other priorities include the development of 
ways to improve the compliance of acute-care 
facilities with existing recommendations and 
guidelines. NNIS will continue to play a vital 
role in these programs by providing data to 
evaluate their efficacy.
SCIEN TIFIC RESO U RCES PRO G RA M : The
Scientific Resources Program procures, man­
ages, and distributes the resources required by 
CDC investigators for research and service 
activities in laboratories and in the field. These 
resources are diverse in nature and demanding 
in scale and timeliness.
Laboratory animal facilities are fully accredited 
by the American Association for Accreditation 
of Laboratory Animal Care and operated under 
the supervision of veterinarians board-certified 
by the American College of Laboratory Animal 
Medicine. The Program conducts protocol re­
views for research and diagnostic activities 
involving laboratory animals.
Cell cultures, cell culture media, and microbio­
logic media are produced using modern
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methods and exhaustive quality assurance 
testing. The program also maintains an active 
applied research program in cell biology, and 
conducts research leading to the development of 
new cell culture systems and cell lines.
The Program procures, prepares, and 
distributes sterile glassware and plasticware, 
and provides packing, shipping, and receiving 
services for etiologic agents, diagnostic speci­
mens, and reagents from the CDC catalog. The 
Program provides services for maintaining and 
developing laboratory equipment.
The Program houses the Center's Biotechnology 
Core Facility, providing instrumentation and 
expertise in DNA and protein/peptide synthesis 
and analysis.
STAN D IN G  CO M M ITTEES AN D  IN TER EST GRO UPS  
O F THE CENTER FO R IN FECTIO U S D ISEASES
The Center for Infectious Diseases Equal 
Employment Opportunity / Affirm ative Action 
Advisory Committee
The staff of the Center for Infectious Diseases is 
committed to the principles of equal employ­
ment opportunity and affirmative action (EEO / 
AA) and supports the CDC Affirmative Employ­
ment Plan. As a part of this effort, the Center 
has established, as a permanent management 
resource, an EEO /A A  Advisory Committee. The 
committee works to achieve racial, ethnic, and 
gender parity in all job categories.
The Center for Infectious Diseases Health and 
Safety Committee and D ivision and Program 
Health and Safety Committees
The Center for Infectious Diseases Surveil­
lance Committee
The Center for Infectious Diseases / National 
Research Council Postdoctoral Fellowship 
Review Committee
The Center for Infectious Diseases Education 
Com m ittee
The Center for Infectious Diseases Grand 
Rounds Committee
The Center for Infectious Diseases Inform ation 
Resources M anagem ent Committee
The Centers for D isease Control / Center for 
Infectious Diseases Child-Care Health Task 
Force
The Center for Infectious D iseases Opportun­
istic Infections W orking Group
The Center for Infectious Diseases Foodborne 
and W aterborne Diseases W orking Group
The Center for Infectious Diseases Year 2000 
O bjectives Committee
The Center for Infectious Diseases Biotechnol­
ogy Core Facility Advisory Committee
The Center for Infectious Diseases Animal Use 
Committee
The Center for Infectious Diseases Awards 
Committee
The Center for Infectious Diseases Project 
Proposal Review Committee
The Center for Infectious Diseases M olecular 
Biology Interest Group
The Center for Infectious D iseases Modern 
Diagnostics Interest Group
The Center for Infectious D iseases Statistics 
Interest Group
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ORGANIZATIONAL MATTERS FOR FURTHER INFORMATION
D etailed inform ation on the organizational structure 
of the Center for Infectious D iseases and a listing of 
D ivision and Program  D irectors and Branch Chiefs 
are available separately.
Partnerships betw een the C enter for Infectious 
D iseases and its Constituencies
In carrying out their mission, the Divisions and 
Programs of the Center for Infectious Diseases work 
with many government, academic, and medical insti­
tutions to which they provide various research, clini­
cal, and consultative services. The following are some 
of the Center's constituencies:
• Federal Agencies
• National Institutes of Health
• Indian Health Service
• Food and Drug Administration
• Department of Agriculture
• Environmental Protection Agency
• State Health Departments
• Association of State and Territorial Health Officials
• Conference of State and Territorial Epidemiologists
• Association of State and Territorial Public Health
Laboratory Directors
• Local Health Departments
• National Association of County Health Officials
• United States Conference of Local Health Officers
• Medical and Biomedical Science Institutions
• Schools of Public Health
• World Health Organization, including Regional Offices
The Center for Infectious D iseases Board of Scientific 
Counselors
The Center for Infectious Diseases Board of Scientific 
Counselors was formed to involve leaders in the 
microbiologic /  infectious disease sciences and com­
munity leaders in the affairs of the Center. The Board 
provides advice and makes recommendations con­
cerning the Center's programs, program priorities, 
program redirection, and program resources. The 
Board meets twice a year.
Employment Opportunities in the 
Center for Infectious Diseases
Employment opportunities in the Center 
for Infectious Diseases are announced 
according to federal regulations in official 
registers, and also in journals and news­
letters and in letters to potential applicants 
and supervisors of potential applicants. 
For further information, contact the CDC 
Personnel Management Office, the Office 
of the Director of the Center for Infectious 
Diseases, or the Office of the Director of 
any Division or Program of the Center.
The CDC Epidemic Intelligence Service 
(EIS) Program in the Center for 
Infectious Diseases
CDC EIS officers assigned to the Center 
for Infectious Diseases participate fully in 
the wide range of scientific and public 
health activities, including epidemiologic 
studies, disease surveillance, public health 
policy development, and epidemic inves­
tigations throughout the United States and 
overseas, particularly in Latin America, 
Africa, and Asia. In addition, EIS officers 
play a prominent role in disseminating 
and communicating scientific and public 
health information by publishing papers 
in scientific journals and giving presenta­
tions at national and international meet­
ings. EIS officers receive personalized on- 
the-job training from epidemiologists, 
laboratory scientists, and statisticians, 
many of whom are internationally re­
nowned experts in their fields; officers 
rapidly develop expertise in epidemiol­
ogic investigation and disease prevention 
and control methodologies, and assume 
substantial responsibility during epidemic 
investigations and in the conduct of 
research projects. EIS officers have played 
a prominent role in identifying and inves­
tigating some of the most important infec­
tious disease problems of recent years,
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such as Legionnaires' disease, toxic shock syn­
drome, HIV infection, and Lyme disease. Major 
initiatives for the 1990s, which will involve EIS 
officers, include the prevention and control of 
HIV infection, the surveillance of Lyme disease, 
the interruption of hepatitis B transmission in 
the United States, the assessment and preven­
tion of opportunistic infections in HIV-infected 
persons, the development of programs to 
prevent diseases in child-care settings, the sur­
veillance of antimicrobial resistance trends in 
the United States, the prevention and control of 
nosocomial infections, and the further devel­
opment of national risk assessment programs 
for foodborne diseases. For further information, 
contact the CDC Epidemiology Program Office.
The Center for Infectious D iseases / National 
Research Council Postdoctoral Fellowship 
Program
Since 1981, the Center for Infectious Diseases 
has been offering Resident Research Associ- 
ateships (Postdoctoral Fellowships and Senior 
Fellowships) under the auspices of the National 
Research Council. These associateships are 
awarded competitively and provide recipients 
an opportunity for a concentrated research expe­
rience under the mentorship of selected staff 
scientists in each of the Divisions and Programs 
of the Center. In 1990, opportunities were avail­
able in 64 scientific areas, representing much of 
the disciplinary expertise of the Center, but 
emphasizing molecular biologic approaches in 
most instances. Candidates will find opportuni­
ties in areas as diverse as the use of poliovirus 
sequencing to track the course of outbreaks and 
epidemics internationally (molecular epidemiol­
ogy), the rapid detection of the agents of bacte­
rial meningitis, the molecular characterization of 
Borrelia burgdorferi, the biochemistry of gonococ­
cal virulence, the molecular basis for Candida 
albicans virulence, the molecular genetics of 
Anopheles mosquitoes, and the pathogenesis of 
simian immunodeficiency virus infection— a 
model for AIDS. For further information, 
contact the Associate Director for Laboratory 
Science, Center for Infectious Diseases.
The Center for Infectious D iseases / Tuskegee 
University College of Veterinary M edicine 
Summer Fellowship Program
The Center for Infectious Diseases/Tuskegee 
University College of Veterinary Medicine Sum­
mer Fellowship Program began in 1988; its pur­
pose is to encourage veterinary medical students 
to consider careers in public service, public 
health, biomedical sciences, and laboratory and 
epidemiologic approaches to the control and 
prevention of infectious diseases. Students and 
mentors are matched according to specific 
interests and goals: there are opportunities for 
gaining experience in microbiologic and mo­
lecular biologic laboratories, in laboratory 
animal medicine, and in epidemiology. This 
program is run in conjunction with CDC's coop­
erative agreement with the Association of Mi­
nority Health Professions Schools.
The Center for Infectious D iseases /
M orehouse University School of M edicine 
Summer Fellowship Program
The Center for Infectious Diseases/M orehouse 
University School of Medicine Summer Fellow­
ship Program began in 1989; its purpose is to 
encourage medical students to consider careers 
in public service, public health, biomedical sci­
ences, and laboratory and epidemiologic ap­
proaches to the control and prevention of infec­
tious diseases. Students and mentors are 
matched according to specific interests and 
goals: there are opportunities for gaining exper­
ience in microbiologic and molecular biologic 
laboratories, and in epidemiology. This pro­
gram is run in conjunction with CDC's coopera­
tive agreement with the Association of Minority 
Health Professions Schools.
the Director and the staff of the Centers for 
Disease Control would be delighted to respond 
to inquiries about career opportunities in any 
of the public health/preventive medicine 
professions
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